Latest On BeiGene, Ltd (BGNE):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-11 13:38 EST | News | BeiGene Goes For Global Growth With Sales And R&D Push | N/A |  |
| 2023-05-04 19:41 EST | News | BeiGene Non-GAAP EPS of -$3.34 beats by $0.32, revenue of $447.8M misses by $1.64M | N/A | |
| 2023-05-03 18:22 EST | News | Immix stock slumps ~20% amid interim data for IMX-110 in colorectal cancer | N/A | |
| 2023-04-20 16:23 EST | News | Novartis, BeiGene tislelizumab meets main goal in gastric/esophagus cancer trial | N/A | |
| 2023-04-17 15:52 EST | News | BeiGene: A Bright Investment In The Battle Against Cancer | N/A | |
| 2023-02-27 08:50 EST | News | BeiGene GAAP EPADS of -$4.29 misses by $0.10, revenue of $380.1M misses by $8.07M | N/A | |
| 2023-02-25 01:20 EST | News | BeiGene Q4 2022 Earnings Preview | N/A | |
| 2023-02-06 12:08 EST | News | Quebec to fund BeiGene's Brukinsa to treat rare blood cancer | N/A | |
| 2023-01-25 11:00 EST | News | BeiGene: Watch FDA Approval And Valuations | N/A | |
| 2023-01-20 12:47 EST | News | BeiGene (BGNE) Presents At 41st Annual Healthcare Conference - Slideshow | N/A | |
| 2023-01-20 01:26 EST | News | BeiGene's Brukinsa gains approval for two additional types of leukemia | N/A | |
| 2023-01-19 13:17 EST | News | BeiGene Brukinsa gets approval in UK for blood cancer subtypes | N/A | |
| 2023-01-18 13:57 EST | News | BeiGene therapies get expanded coverage on China's national reimbursement drug list | N/A | |
| 2023-01-14 16:39 EST | News | Stocks To Watch: Economic Reports, Earnings Blockbusters And Political Minefields Lie Ahead Next Week | N/A | |
| 2022-12-30 17:16 EST | News | China accepts BeiGene's supplemental license application for treatment of liver cancer | N/A | |
| 2022-12-17 07:33 EST | News | Chinese pharmas and biotechs risk of delisting averted as US regulators review audits | N/A | |
| 2022-12-13 16:12 EST | News | BeiGene says Brukinsa bests J&J's Imbruvica in progression-free survival for leukemia | N/A | |
| 2022-11-28 22:15 EST | News | BeiGene Q3 2022 Earnings Preview | N/A | |
| 2022-11-17 14:03 EST | News | BeiGene Brukinsa gets approval in EU for expanded use in leukemia | N/A | |
| 2022-11-14 19:04 EST | News | Surging BeiGene Catches Case Of Forex Flu | N/A | |
| 2022-11-09 16:44 EST | News | BeiGene GAAP EPADS of -$5.39 misses by $1.54, revenue of $387.63M beats by $10.18M | N/A | |
| 2022-11-02 10:15 EST | News | BeiGene rises as Brukinsa approved in EU for expanded use in blood cancer subtype | N/A | |
| 2022-10-26 09:43 EST | News | BeiGene blood cancer drug Brukinsa gets approval in 6 Latin American countries | N/A | |
| 2022-10-19 18:29 EST | News | Zymeworks surges 14% on license deal with Jazz for cancer drug zanidatamab | N/A | |
| 2022-10-14 10:45 EST | News | BeiGene's blood cancer drug Brukinsa gets EMA panel nod for EU approval | N/A | |
| 2022-10-13 20:20 EST | News | BeiGene upgraded to buy at Guggenheim on improved confidence in Brukinsa potential | N/A | |
| 2022-10-12 13:32 EST | News | BeiGene Brukinsa shows better survival benefit vs Imbruvica in blood cancer patients in trial | N/A | |
| 2022-09-21 01:43 EST | News | BeiGene A Hold Despite Rapid Revenue Growth | N/A | |
| 2022-09-20 08:55 EST | News | BeiGene: Best Biotech Industry Stock Bet Say Portfolio Wealth Builders | N/A | |
| 2022-09-16 19:45 EST | News | EMA panel recommends extending indication for BeiGene's cancer drug Brukinsa | N/A | |
| 2022-08-16 01:19 EST | News | BeiGene, McKesson team up to develop data, tools for US community oncology care | N/A | |
| 2022-08-09 14:07 EST | News | Novartis/BeiGene's tislelizumab matches Bayer's Nexavar in survival benefit for liver cancer patients in trial | N/A | |
| 2022-08-04 20:28 EST | News | BeiGene GAAP EPADS of -$5.56 misses by $1.45, revenue of $341.57M beats by $30.5M | N/A | |
| 2022-08-04 20:27 EST | News | U.S.-listed shares of BeiGene rise after Q2 revenue more than doubles Y/Y | N/A | |
| 2022-07-14 15:04 EST | News | FDA defers action on Novartis/BeiGene's tislelizumab for esophagus cancer citing inspection woes | N/A | |
| 2022-07-12 19:41 EST | News | Leap Therapeutics begins trials of DKN-01 in gastric/colorectal cancers | N/A | |
| 2022-07-06 15:06 EST | News | BeiGene in pact with InnoRNA to develop messenger RNA-based therapies | N/A | |
| 2022-06-30 21:23 EST | News | Novartis, BeiGene tislelizumab/chemo improves survival of esophageal cancer patients in trial | N/A | |
| 2022-06-21 19:14 EST | News | BeiGene adds 12% as anti-PD-1 Inhibitor undergoes regulatory review in China | N/A | |
| 2022-06-13 16:31 EST | News | BeiGene down 9% as FDA extends action date for Brukinsa supplemental approval | N/A | |
| 2022-06-11 12:36 EST | News | BeiGene stock rises as tislelizumab gets approval in China for head/neck cancer subtype | N/A | |
| 2022-05-05 16:02 EST | News | BeiGene GAAP EPADS of -$4.24 beats by $1.08, revenue of $306.63M beats by $6.22M | N/A | |
| 2022-05-04 17:22 EST | News | Amgen, BeiGene's Blincyto gets conditional approval in China to treat blood cancer subtype in children | N/A | |
| 2022-04-29 16:56 EST | News | BeiGene stock rises 10% as biotech breaks ground at new manufacturing site in New Jersey | N/A | |
| 2022-04-28 23:52 EST | News | BeiGene Brukinsa gets approval in Uruguay to treat certain blood cancers | N/A | |
| 2022-04-27 15:22 EST | News | BeiGene says late-stage trial for PD-1 inhibitor met main goal in esophageal cancer | N/A | |
| 2022-04-26 05:49 EST | News | BeiGene and Biocytogen in licensing pact for antibody therapies | N/A | |
| 2022-04-19 15:22 EST | News | BeiGene, Novartis tislelizumab shows survival benefit in head/neck cancer in updated phase 3 data | N/A | |
| 2022-04-18 09:15 EST | News | BeiGene, Novartis' tislelizumab gets approval in China for esophagus cancer | N/A | |
| 2022-04-11 14:12 EST | News | Beigene's Brukinsa bests Imbruvica in overall response in leukemia trial | N/A | |
About BeiGene, Ltd (BGNE):
BeiGene, Ltd., a commercial-stage biotechnology company, engages in discovering, developing, manufacturing, and commercializing medicines for cancer therapeutics in the People's Republic of China and the United States. Its commercial products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and BAT1706 to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat various lymphomas; Tislelizumab, an anti-PD-1 antibody to treat various solid and hematological cancers; Lifirafenib and BGB-3245 to treat various malignancies, such as melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company was incorporated in 2010 and is headquartered in Beijing, the People's Republic of China.
General
- Name BeiGene, Ltd
- Symbol BGNE
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 5,300
- Fiscal Year EndDecember
- IPO Date2016-02-03
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.beigene.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 86.94
- Price/Book (Most Recent Quarter) 7.61
- Enterprise Value Revenue 80.69
View More
Financials
- Most Recent Quarter 2020-12-31
- Operating Margin -537%
- Return on Assets -29%
- Return on Equity -66%
- Revenue 308.87 million
- Earnings Per Share -$11.29
- Revenue Per Share $3.7
- Gross Profit -1056660000
- Quarterly Earnings Growth 75.9%
View More
Highlights
- Market Capitalization 30.31 billion
- EBITDA -678579008
- PE Ratio -35.53
- Analyst Target Price $346.22
- Book Value Per Share $42.24
View More
Share Statistics
- Shares Outstanding 91.57 million
- Shares Float 47.48 million
- % Held by Insiders 2059%
- % Held by Institutions 66.29%
- Shares Short 2.2 million
- Shares Short Prior Month 2.2 million
- Short Ratio 7.02
- Short % of Shares Outstanding 2%
View More
Technicals
- Beta 0.86
- 52 Week High $388.97
- 52 Week Low $118.55
- 50 Day Moving Average 336.5
- 200 Day Moving Average 293.03
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
BeiGene, Ltd (BGNE) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
BeiGene, Ltd (BGNE) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-02-25 | $100.1 million | -$5.20 | -$4.22 | -23.13% |
| 2020-09-30 | 2020-11-05 | $N/A | -$4.81 | -$4.18 | -15.07% |
| 2020-06-30 | 2020-08-06 | $N/A | -$4.31 | -$4.72 | 8.73% |
| 2020-03-31 | 2020-05-11 | $52.06 million | -$4.70 | -$4.85 | 3.04% |
| 2019-12-31 | 2020-03-02 | $56.89 million | -$6.39 | -$4.53 | -41.16% |
| 2019-09-30 | 2019-11-12 | $50.14 million | -$5.11 | -$3.56 | -43.34% |
| 2019-06-30 | 2019-08-08 | $243.35 million | -$1.43 | -$3.01 | 52.47% |
| 2019-03-31 | 2019-05-09 | $77.83 million | -$2.81 | -$3.15 | 10.65% |
| 2018-12-31 | 2019-02-27 | $58.67 million | -$4.52 | -$2.99 | -50.97% |
| 2018-09-30 | 2018-11-07 | $54.2 million | -$2.53 | -$2.97 | 14.9% |
| 2018-06-30 | 2018-08-09 | $52.8 million | -$2.92 | -$2.12 | -37.9% |
| 2018-03-31 | 2018-05-09 | $32.54 million | -$2.03 | -$1.74 | -16.83% |
| 2017-12-31 | 2018-02-28 | $18.17 million | -$2.19 | -$1.75 | -25.38% |
| 2017-09-30 | 2017-11-13 | $220.21 million | $2.54 | -$1.39 | 282.73% |
| 2017-06-30 | 2017-08-09 | $N/A | -$1.52 | -$1.20 | -27.02% |
| 2017-03-31 | 2017-05-10 | $N/A | -$1.27 | -$0.87 | -45.43% |
| 2016-12-31 | 2017-03-22 | $1.07 million | -$1.05 | -$0.86 | -22.45% |
| 2016-09-30 | 2016-11-10 | $-393000 | -$1.08 | -$0.78 | -38.46% |
| 2016-06-30 | 2016-08-10 | $393000 | -$0.73 | -$0.68 | -8.15% |
| 2016-03-31 | 2016-05-11 | $677000 | -$0.97 | -$0.63 | -53.17% |
| 2015-12-31 | 2016-03-30 | $4.68 million | -$3.05 | -$1.06 | -187.74% |
BeiGene, Ltd (BGNE) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
BeiGene, Ltd (BGNE) Chart:
BeiGene, Ltd (BGNE) News:
Below you will find a list of latest news for BeiGene, Ltd (BGNE) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
BeiGene, Ltd (BGNE) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2025-05-16 | 105 | 0 | CALL | 0 | 0 | 53.42 | TRUE | 0 | 0 |
| 2025-05-16 | 110 | 0 | CALL | 0 | 0 | 49.26 | TRUE | 0 | 0 |
| 2025-05-16 | 115 | 0 | CALL | 0 | 0 | 44.58 | TRUE | 0 | 0 |
| 2025-05-16 | 120 | 0 | CALL | 0 | 0 | 44.49 | TRUE | 0 | 0 |
| 2025-05-16 | 125 | 0 | CALL | 0 | 0 | 41.76 | TRUE | 0 | 0 |
| 2025-05-16 | 130 | 0 | CALL | 0 | 0 | 41.87 | TRUE | 0 | 0 |
| 2025-05-16 | 135 | 0 | CALL | 0 | 0 | 41.17 | TRUE | 0 | 0 |
| 2025-05-16 | 140 | 0 | CALL | 0 | 0 | 41.75 | TRUE | 0 | 0 |
| 2025-05-16 | 145 | 0 | CALL | 0 | 0 | 40.6 | TRUE | 0 | 0 |
| 2025-05-16 | 150 | 0 | CALL | 0 | 0 | 42.07 | TRUE | 0 | 0 |
| 2025-05-16 | 155 | 0 | CALL | 0 | 0 | 41.25 | TRUE | 0 | 0 |
| 2025-05-16 | 160 | 0 | CALL | 0 | 150 | 42.35 | TRUE | 0 | 0 |
| 2025-05-16 | 165 | 0 | CALL | 0 | 0 | 42.15 | TRUE | 0 | 0 |
| 2025-05-16 | 170 | 0 | CALL | 0 | 0 | 42.19 | TRUE | 0 | 0 |
| 2025-05-16 | 175 | 0 | CALL | 0 | 0 | 41.95 | TRUE | 0 | 0 |
| 2025-05-16 | 180 | 0 | CALL | 0 | 1 | 42.15 | TRUE | 0 | 0 |
| 2025-05-16 | 185 | 0 | CALL | 0 | 0 | 41.97 | FALSE | 0 | 0 |
| 2025-05-16 | 190 | 0 | CALL | 0 | 13 | 41.46 | FALSE | 0 | 0 |
| 2025-05-16 | 195 | 0 | CALL | 0 | 2 | 41.39 | FALSE | 0 | 0 |
| 2025-05-16 | 200 | 0 | CALL | 0 | 152 | 41 | FALSE | 0 | 0 |
| 2025-05-16 | 210 | 0 | CALL | 0 | 4 | 41.4 | FALSE | 0 | 0 |
| 2025-05-16 | 220 | 0 | CALL | 0 | 16 | 41.39 | FALSE | 0 | 0 |
| 2025-05-16 | 230 | 6 | CALL | 0 | 7 | 41.02 | FALSE | 0 | 0 |
| 2025-05-16 | 240 | 0 | CALL | 0 | 6 | 42.16 | FALSE | 0 | 0 |
| 2025-05-16 | 250 | 0 | CALL | 0 | 2 | 41.27 | FALSE | 0 | 0 |
| 2025-05-16 | 260 | 0 | CALL | 0 | 4 | 41.2 | FALSE | 0 | 0 |
| 2025-05-16 | 270 | 0 | CALL | 0 | 14 | 46.35 | FALSE | 0 | 0 |
| 2025-05-16 | 280 | 1.95 | CALL | 0 | 2 | 44.77 | FALSE | 0 | 0 |
| 2025-05-16 | 290 | 1.75 | CALL | 0 | 2 | 46.44 | FALSE | 0 | 0 |
| 2025-05-16 | 300 | 0 | CALL | 0 | 3 | 55.62 | FALSE | 0 | 0 |
| 2025-05-16 | 310 | 0 | CALL | 0 | 0 | 55.83 | FALSE | 0 | 0 |
| 2025-05-16 | 320 | 0 | CALL | 0 | 0 | 58.34 | FALSE | 0 | 0 |
| 2025-05-16 | 330 | 0 | CALL | 0 | 1 | 60.73 | FALSE | 0 | 0 |
| 2025-05-16 | 340 | 0 | CALL | 0 | 0 | 63.03 | FALSE | 0 | 0 |
| 2025-05-16 | 350 | 0 | CALL | 0 | 0 | 65.23 | FALSE | 0 | 0 |
| 2025-05-16 | 360 | 0 | CALL | 0 | 2 | 67.35 | FALSE | 0 | 0 |
| 2025-05-16 | 105 | 0 | PUT | 0 | 0 | 71.17 | FALSE | 0 | 0 |
| 2025-05-16 | 110 | 0 | PUT | 0 | 0 | 66.46 | FALSE | 0 | 0 |
| 2025-05-16 | 115 | 0 | PUT | 0 | 0 | 61.94 | FALSE | 0 | 0 |
| 2025-05-16 | 120 | 0 | PUT | 0 | 0 | 57.59 | FALSE | 0 | 0 |
| 2025-05-16 | 125 | 0 | PUT | 0 | 0 | 53.4 | FALSE | 0 | 0 |
| 2025-05-16 | 130 | 0 | PUT | 0 | 0 | 49.34 | FALSE | 0 | 0 |
| 2025-05-16 | 135 | 0 | PUT | 0 | 0 | 45.4 | FALSE | 0 | 0 |
| 2025-05-16 | 140 | 0 | PUT | 0 | 1 | 41.56 | FALSE | 0 | 0 |
| 2025-05-16 | 145 | 0 | PUT | 0 | 60 | 41.07 | FALSE | 0 | 0 |
| 2025-05-16 | 150 | 0 | PUT | 0 | 43 | 40.49 | FALSE | 0 | 0 |
| 2025-05-16 | 155 | 0 | PUT | 0 | 80 | 40.14 | FALSE | 0 | 0 |
| 2025-05-16 | 160 | 0 | PUT | 0 | 183 | 40.35 | FALSE | 0 | 0 |
| 2025-05-16 | 165 | 0 | PUT | 0 | 18 | 40.05 | FALSE | 0 | 0 |
| 2025-05-16 | 170 | 0 | PUT | 0 | 0 | 40.11 | FALSE | 0 | 0 |
| 2025-05-16 | 175 | 0 | PUT | 0 | 120 | 39.96 | FALSE | 0 | 0 |
| 2025-05-16 | 180 | 0 | PUT | 0 | 1 | 40.45 | FALSE | 0 | 0 |
| 2025-05-16 | 185 | 0 | PUT | 0 | 1 | 40.39 | TRUE | 0 | 0 |
| 2025-05-16 | 190 | 0 | PUT | 0 | 0 | 39.85 | TRUE | 0 | 0 |
| 2025-05-16 | 195 | 0 | PUT | 0 | 0 | 40.05 | TRUE | 0 | 0 |
| 2025-05-16 | 200 | 0 | PUT | 0 | 150 | 39.67 | TRUE | 0 | 0 |
| 2025-05-16 | 210 | 0 | PUT | 0 | 0 | 39.74 | TRUE | 0 | 0 |
| 2025-05-16 | 220 | 0 | PUT | 0 | 1 | 39.44 | TRUE | 0 | 0 |
| 2025-05-16 | 230 | 0 | PUT | 0 | 1 | 38.89 | TRUE | 0 | 0 |
| 2025-05-16 | 240 | 0 | PUT | 0 | 0 | 39.65 | TRUE | 0 | 0 |
| 2025-05-16 | 250 | 0 | PUT | 0 | 162 | 41.55 | TRUE | 0 | 0 |
| 2025-05-16 | 260 | 0 | PUT | 0 | 0 | 38.64 | TRUE | 0 | 0 |
| 2025-05-16 | 270 | 0 | PUT | 0 | 38 | 53.33 | TRUE | 0 | 0 |
| 2025-05-16 | 280 | 0 | PUT | 0 | 0 | 56.87 | TRUE | 0 | 0 |
| 2025-05-16 | 290 | 0 | PUT | 0 | 0 | 60.24 | TRUE | 0 | 0 |
| 2025-05-16 | 300 | 0 | PUT | 0 | 0 | 63.45 | TRUE | 0 | 0 |
| 2025-05-16 | 310 | 0 | PUT | 0 | 0 | 66.52 | TRUE | 0 | 0 |
| 2025-05-16 | 320 | 0 | PUT | 0 | 0 | 69.45 | TRUE | 0 | 0 |
| 2025-05-16 | 330 | 0 | PUT | 0 | 0 | 72.27 | TRUE | 0 | 0 |
| 2025-05-16 | 340 | 0 | PUT | 0 | 0 | 74.98 | TRUE | 0 | 0 |
| 2025-05-16 | 350 | 0 | PUT | 0 | 0 | 77.59 | TRUE | 0 | 0 |
| 2025-05-16 | 360 | 0 | PUT | 0 | 0 | 80.12 | TRUE | 0 | 0 |
| 2025-08-15 | 100 | 0 | CALL | 0 | 0 | 46.09 | TRUE | 0 | 0 |
| 2025-08-15 | 105 | 0 | CALL | 0 | 0 | 41.52 | TRUE | 0 | 0 |
| 2025-08-15 | 110 | 0 | CALL | 0 | 0 | 42.27 | TRUE | 0 | 0 |
| 2025-08-15 | 115 | 0 | CALL | 0 | 0 | 41.75 | TRUE | 0 | 0 |
| 2025-08-15 | 120 | 0 | CALL | 0 | 0 | 41.1 | TRUE | 0 | 0 |
| 2025-08-15 | 125 | 0 | CALL | 0 | 0 | 40.32 | TRUE | 0 | 0 |
| 2025-08-15 | 130 | 0 | CALL | 0 | 0 | 40.53 | TRUE | 0 | 0 |
| 2025-08-15 | 135 | 0 | CALL | 0 | 0 | 39.42 | TRUE | 0 | 0 |
| 2025-08-15 | 140 | 0 | CALL | 0 | 8 | 40.7 | TRUE | 0 | 0 |
| 2025-08-15 | 145 | 0 | CALL | 0 | 4 | 40.09 | TRUE | 0 | 0 |
| 2025-08-15 | 150 | 0 | CALL | 0 | 0 | 40.33 | TRUE | 0 | 0 |
| 2025-08-15 | 155 | 0 | CALL | 0 | 0 | 41.18 | TRUE | 0 | 0 |
| 2025-08-15 | 160 | 0 | CALL | 0 | 0 | 40.66 | TRUE | 0 | 0 |
| 2025-08-15 | 165 | 0 | CALL | 0 | 0 | 40.76 | TRUE | 0 | 0 |
| 2025-08-15 | 170 | 0 | CALL | 0 | 0 | 40.51 | TRUE | 0 | 0 |
| 2025-08-15 | 175 | 0 | CALL | 0 | 0 | 40.79 | TRUE | 0 | 0 |
| 2025-08-15 | 180 | 0 | CALL | 0 | 0 | 40.84 | TRUE | 0 | 0 |
| 2025-08-15 | 185 | 0 | CALL | 0 | 1 | 40.67 | FALSE | 0 | 0 |
| 2025-08-15 | 190 | 0 | CALL | 0 | 0 | 40.92 | FALSE | 0 | 0 |
| 2025-08-15 | 195 | 0 | CALL | 0 | 1 | 40.2 | FALSE | 0 | 0 |
| 2025-08-15 | 200 | 0 | CALL | 0 | 1 | 41.65 | FALSE | 0 | 0 |
| 2025-08-15 | 210 | 0 | CALL | 0 | 1 | 39.74 | FALSE | 0 | 0 |
| 2025-08-15 | 220 | 0 | CALL | 0 | 0 | 40.31 | FALSE | 0 | 0 |
| 2025-08-15 | 230 | 0 | CALL | 0 | 0 | 40.07 | FALSE | 0 | 0 |
| 2025-08-15 | 240 | 0 | CALL | 0 | 0 | 40 | FALSE | 0 | 0 |
| 2025-08-15 | 250 | 0 | CALL | 0 | 0 | 40.27 | FALSE | 0 | 0 |
| 2025-08-15 | 260 | 0 | CALL | 0 | 0 | 39.89 | FALSE | 0 | 0 |
| 2025-08-15 | 100 | 0 | PUT | 0 | 0 | 59.66 | FALSE | 0 | 0 |
| 2025-08-15 | 105 | 0 | PUT | 0 | 0 | 55.85 | FALSE | 0 | 0 |
| 2025-08-15 | 110 | 0 | PUT | 0 | 0 | 52.2 | FALSE | 0 | 0 |
| 2025-08-15 | 115 | 0 | PUT | 0 | 0 | 48.71 | FALSE | 0 | 0 |
| 2025-08-15 | 120 | 0 | PUT | 0 | 0 | 45.34 | FALSE | 0 | 0 |
| 2025-08-15 | 125 | 0 | PUT | 0 | 0 | 42.1 | FALSE | 0 | 0 |
| 2025-08-15 | 130 | 0 | PUT | 0 | 0 | 38.96 | FALSE | 0 | 0 |
| 2025-08-15 | 135 | 0 | PUT | 0 | 0 | 37.74 | FALSE | 0 | 0 |
| 2025-08-15 | 140 | 0 | PUT | 0 | 0 | 38.17 | FALSE | 0 | 0 |
| 2025-08-15 | 145 | 0 | PUT | 0 | 0 | 38.46 | FALSE | 0 | 0 |
| 2025-08-15 | 150 | 0 | PUT | 0 | 0 | 38.75 | FALSE | 0 | 0 |
| 2025-08-15 | 155 | 0 | PUT | 0 | 0 | 38.92 | FALSE | 0 | 0 |
| 2025-08-15 | 160 | 0 | PUT | 0 | 0 | 38.99 | FALSE | 0 | 0 |
| 2025-08-15 | 165 | 0 | PUT | 0 | 0 | 39.07 | FALSE | 0 | 0 |
| 2025-08-15 | 170 | 0 | PUT | 0 | 0 | 39.07 | FALSE | 0 | 0 |
| 2025-08-15 | 175 | 0 | PUT | 0 | 0 | 39.65 | FALSE | 0 | 0 |
| 2025-08-15 | 180 | 0 | PUT | 0 | 0 | 38.95 | FALSE | 0 | 0 |
| 2025-08-15 | 185 | 0 | PUT | 0 | 0 | 39.73 | TRUE | 0 | 0 |
| 2025-08-15 | 190 | 0 | PUT | 0 | 0 | 39.31 | TRUE | 0 | 0 |
| 2025-08-15 | 195 | 0 | PUT | 0 | 0 | 39.46 | TRUE | 0 | 0 |
| 2025-08-15 | 200 | 0 | PUT | 0 | 0 | 39.32 | TRUE | 0 | 0 |
| 2025-08-15 | 210 | 0 | PUT | 0 | 2 | 38.46 | TRUE | 0 | 0 |
| 2025-08-15 | 220 | 0 | PUT | 0 | 0 | 38.69 | TRUE | 0 | 0 |
| 2025-08-15 | 230 | 0 | PUT | 0 | 0 | 38.26 | TRUE | 0 | 0 |
| 2025-08-15 | 240 | 0 | PUT | 0 | 0 | 38.74 | TRUE | 0 | 0 |
| 2025-08-15 | 250 | 0 | PUT | 0 | 0 | 38.38 | TRUE | 0 | 0 |
| 2025-08-15 | 260 | 0 | PUT | 0 | 0 | 38.35 | TRUE | 0 | 0 |
Latest BGNE Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 50 | $130.3 |
| Jun 13, 2022 7:59 PM EST | 1 | $130.4 |
| Jun 13, 2022 7:59 PM EST | 50 | $130.44 |
| Jun 13, 2022 7:59 PM EST | 26 | $130.45 |
| Jun 13, 2022 7:59 PM EST | 70 | $130.45 |
BeiGene, Ltd (BGNE) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-07-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000091/0001651308-20-000091-index.htm |
| 2020-02-07 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1651308/000031506620000852/0000315066-20-000852-index.htm |
| 2020-01-02 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000089924320000027/0000899243-20-000027-index.htm |
| 2020-07-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000089924320019383/0000899243-20-019383-index.htm |
| 2020-08-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000089924320023107/0000899243-20-023107-index.htm |
| 2020-08-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000089924320023319/0000899243-20-023319-index.htm |
| 2020-08-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000089924320023386/0000899243-20-023386-index.htm |
| 2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000090266420002459/0000902664-20-002459-index.htm |
| 2020-07-14 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000090266420002659/0000902664-20-002659-index.htm |
| 2020-07-14 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1651308/000090266420002660/0000902664-20-002660-index.htm |
| 2019-11-19 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1651308/000104746919006397/0001047469-19-006397-index.htm |
| 2019-11-29 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1651308/000104746919006563/0001047469-19-006563-index.htm |
| 2019-12-06 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1651308/000104746919006715/0001047469-19-006715-index.htm |
| 2020-04-17 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1651308/000104746920002398/0001047469-20-002398-index.htm |
| 2020-04-28 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1651308/000104746920002658/0001047469-20-002658-index.htm |
| 2020-05-11 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers | https://www.sec.gov/Archives/edgar/data/1651308/000104746920002987/0001047469-20-002987-index.htm |
| 2020-05-11 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers | https://www.sec.gov/Archives/edgar/data/1651308/000104746920002988/0001047469-20-002988-index.htm |
| 2019-11-06 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1651308/000110465919060588/0001104659-19-060588-index.htm |
| 2020-01-07 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1651308/000110465920002041/0001104659-20-002041-index.htm |
| 2020-02-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1651308/000110465920013792/0001104659-20-013792-index.htm |
| 2020-03-30 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1651308/000110465920040357/0001104659-20-040357-index.htm |
| 2020-07-13 | 424B2 | Prospectus [Rule 424(b)(2)] | https://www.sec.gov/Archives/edgar/data/1651308/000110465920082903/0001104659-20-082903-index.htm |
| 2020-07-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000110465920082907/0001104659-20-082907-index.htm |
| 2020-07-17 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1651308/000110465920084573/0001104659-20-084573-index.htm |
| 2020-09-28 | PRER14A | Preliminary Proxy Soliciting materials | https://www.sec.gov/Archives/edgar/data/1651308/000110465920109298/0001104659-20-109298-index.htm |
| 2020-10-09 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1651308/000110465920113904/0001104659-20-113904-index.htm |
| 2020-01-08 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1651308/000119312520003926/0001193125-20-003926-index.htm |
| 2020-07-16 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1651308/000119312520194077/0001193125-20-194077-index.htm |
| 2020-01-10 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1651308/000142284920000005/0001422849-20-000005-index.htm |
| 2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000163859920000631/0001638599-20-000631-index.htm |
| 2020-07-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000163859920000663/0001638599-20-000663-index.htm |
| 2019-10-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000092/0001651308-19-000092-index.htm |
| 2019-10-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000098/0001651308-19-000098-index.htm |
| 2019-11-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000101/0001651308-19-000101-index.htm |
| 2019-11-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000102/0001651308-19-000102-index.htm |
| 2019-11-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000103/0001651308-19-000103-index.htm |
| 2019-11-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000104/0001651308-19-000104-index.htm |
| 2019-11-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000105/0001651308-19-000105-index.htm |
| 2019-11-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000110/0001651308-19-000110-index.htm |
| 2019-11-12 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000111/0001651308-19-000111-index.htm |
| 2019-11-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000115/0001651308-19-000115-index.htm |
| 2019-11-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000116/0001651308-19-000116-index.htm |
| 2019-11-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000117/0001651308-19-000117-index.htm |
| 2019-11-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000118/0001651308-19-000118-index.htm |
| 2019-11-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000119/0001651308-19-000119-index.htm |
| 2019-11-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000120/0001651308-19-000120-index.htm |
| 2019-11-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000123/0001651308-19-000123-index.htm |
| 2019-12-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000126/0001651308-19-000126-index.htm |
| 2019-12-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000131/0001651308-19-000131-index.htm |
| 2019-12-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000134/0001651308-19-000134-index.htm |
| 2019-12-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000135/0001651308-19-000135-index.htm |
| 2019-12-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000136/0001651308-19-000136-index.htm |
| 2019-12-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000140/0001651308-19-000140-index.htm |
| 2019-12-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000142/0001651308-19-000142-index.htm |
| 2019-12-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000148/0001651308-19-000148-index.htm |
| 2020-01-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000003/0001651308-20-000003-index.htm |
| 2020-01-02 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000004/0001651308-20-000004-index.htm |
| 2020-01-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000006/0001651308-20-000006-index.htm |
| 2020-01-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000008/0001651308-20-000008-index.htm |
| 2020-01-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000009/0001651308-20-000009-index.htm |
| 2020-01-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000011/0001651308-20-000011-index.htm |
| 2020-02-07 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000014/0001651308-20-000014-index.htm |
| 2020-02-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000015/0001651308-20-000015-index.htm |
| 2020-03-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000018/0001651308-20-000018-index.htm |
| 2020-03-02 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000020/0001651308-20-000020-index.htm |
| 2020-03-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000021/0001651308-20-000021-index.htm |
| 2020-03-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000022/0001651308-20-000022-index.htm |
| 2020-03-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000025/0001651308-20-000025-index.htm |
| 2020-03-23 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000029/0001651308-20-000029-index.htm |
| 2020-03-23 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000030/0001651308-20-000030-index.htm |
| 2020-03-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000034/0001651308-20-000034-index.htm |
| 2020-03-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000037/0001651308-20-000037-index.htm |
| 2020-04-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000041/0001651308-20-000041-index.htm |
| 2020-04-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000043/0001651308-20-000043-index.htm |
| 2020-04-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000044/0001651308-20-000044-index.htm |
| 2020-05-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000045/0001651308-20-000045-index.htm |
| 2020-05-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000046/0001651308-20-000046-index.htm |
| 2020-05-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000053/0001651308-20-000053-index.htm |
| 2020-05-11 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000056/0001651308-20-000056-index.htm |
| 2020-05-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000058/0001651308-20-000058-index.htm |
| 2020-06-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000060/0001651308-20-000060-index.htm |
| 2020-06-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000061/0001651308-20-000061-index.htm |
| 2020-06-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000063/0001651308-20-000063-index.htm |
| 2020-06-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000064/0001651308-20-000064-index.htm |
| 2020-06-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000065/0001651308-20-000065-index.htm |
| 2020-06-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000066/0001651308-20-000066-index.htm |
| 2020-06-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000067/0001651308-20-000067-index.htm |
| 2020-06-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000068/0001651308-20-000068-index.htm |
| 2020-06-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000070/0001651308-20-000070-index.htm |
| 2020-06-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000072/0001651308-20-000072-index.htm |
| 2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000073/0001651308-20-000073-index.htm |
| 2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000074/0001651308-20-000074-index.htm |
| 2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000075/0001651308-20-000075-index.htm |
| 2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000076/0001651308-20-000076-index.htm |
| 2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000077/0001651308-20-000077-index.htm |
| 2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000078/0001651308-20-000078-index.htm |
| 2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000079/0001651308-20-000079-index.htm |
| 2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000080/0001651308-20-000080-index.htm |
| 2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000081/0001651308-20-000081-index.htm |
| 2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000082/0001651308-20-000082-index.htm |
| 2020-06-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000084/0001651308-20-000084-index.htm |
| 2020-06-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000085/0001651308-20-000085-index.htm |
| 2020-06-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000086/0001651308-20-000086-index.htm |
| 2020-06-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000087/0001651308-20-000087-index.htm |
| 2020-07-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000088/0001651308-20-000088-index.htm |
| 2020-07-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000089/0001651308-20-000089-index.htm |
| 2020-07-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000091/0001651308-20-000091-index.htm |
| 2020-07-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000092/0001651308-20-000092-index.htm |
| 2020-07-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000093/0001651308-20-000093-index.htm |
| 2020-07-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000094/0001651308-20-000094-index.htm |
| 2020-07-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000095/0001651308-20-000095-index.htm |
| 2020-07-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000097/0001651308-20-000097-index.htm |
| 2020-07-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000098/0001651308-20-000098-index.htm |
| 2020-07-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000101/0001651308-20-000101-index.htm |
| 2020-07-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000102/0001651308-20-000102-index.htm |
| 2020-07-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000103/0001651308-20-000103-index.htm |
| 2020-07-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000104/0001651308-20-000104-index.htm |
| 2020-07-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000105/0001651308-20-000105-index.htm |
| 2020-07-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000106/0001651308-20-000106-index.htm |
| 2020-08-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000108/0001651308-20-000108-index.htm |
| 2020-08-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000110/0001651308-20-000110-index.htm |
| 2020-08-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000116/0001651308-20-000116-index.htm |
| 2020-08-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000117/0001651308-20-000117-index.htm |
| 2020-08-06 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000119/0001651308-20-000119-index.htm |
| 2020-08-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000120/0001651308-20-000120-index.htm |
| 2020-08-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000121/0001651308-20-000121-index.htm |
| 2020-08-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000122/0001651308-20-000122-index.htm |
| 2020-08-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000125/0001651308-20-000125-index.htm |
| 2020-08-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000138/0001651308-20-000138-index.htm |
| 2020-08-26 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000140/0001651308-20-000140-index.htm |
| 2020-08-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000141/0001651308-20-000141-index.htm |
| 2020-08-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000144/0001651308-20-000144-index.htm |
| 2020-09-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000145/0001651308-20-000145-index.htm |
| 2020-09-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000146/0001651308-20-000146-index.htm |
| 2020-09-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000147/0001651308-20-000147-index.htm |
| 2020-09-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000151/0001651308-20-000151-index.htm |
| 2020-09-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000152/0001651308-20-000152-index.htm |
| 2020-09-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000153/0001651308-20-000153-index.htm |
| 2020-09-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000160/0001651308-20-000160-index.htm |
| 2020-09-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000161/0001651308-20-000161-index.htm |
| 2020-09-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000162/0001651308-20-000162-index.htm |
| 2020-09-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000174/0001651308-20-000174-index.htm |
| 2020-09-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000175/0001651308-20-000175-index.htm |
| 2020-09-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000176/0001651308-20-000176-index.htm |
| 2020-09-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000180/0001651308-20-000180-index.htm |
| 2020-10-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000182/0001651308-20-000182-index.htm |
| 2020-10-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000186/0001651308-20-000186-index.htm |
| 2020-10-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000193/0001651308-20-000193-index.htm |
| 2020-10-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000194/0001651308-20-000194-index.htm |
| 2020-10-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000195/0001651308-20-000195-index.htm |
| 2020-10-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000196/0001651308-20-000196-index.htm |
| 2020-10-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000197/0001651308-20-000197-index.htm |
| 2020-11-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000198/0001651308-20-000198-index.htm |
| 2020-11-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000207/0001651308-20-000207-index.htm |
| 2020-11-05 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000208/0001651308-20-000208-index.htm |
BeiGene, Ltd (BGNE) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of BeiGene, Ltd (BGNE). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 2059%Institutional Ownership: 6629%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-05-19 | Donald W. Glazer | Director | Sell | 10,000.00 | 169.84 | 1,698,400.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000058/0001651308-20-000058-index.htm |
| 2019-11-18 | Howard Liang | CFO & Chief Strategy Officer | Sell | 400.00 | 198.93 | 79,572.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000119/0001651308-19-000119-index.htm |
| 2020-06-08 | Howard Liang | CFO & Chief Strategy Officer | Sell | 453.00 | 170.84 | 77,390.52 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000067/0001651308-20-000067-index.htm |
| 2020-06-29 | Howard Liang | CFO & Chief Strategy Officer | Sell | 300.00 | 191.23 | 57,368.01 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000088/0001651308-20-000088-index.htm |
| 2020-09-14 | Howard Liang | CFO & Chief Strategy Officer | Sell | 103.00 | 252.59 | 26,016.53 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000152/0001651308-20-000152-index.htm |
| 2020-10-05 | Howard Liang | CFO & Chief Strategy Officer | Sell | 300.00 | 304.15 | 91,245.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000194/0001651308-20-000194-index.htm |
| 2019-11-04 | Jane Huang | CMO, Hematology | Sell | 300.00 | 192.77 | 57,831.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000105/0001651308-19-000105-index.htm |
| 2019-11-18 | Jane Huang | CMO, Hematology | Sell | 100.00 | 198.93 | 19,893.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000118/0001651308-19-000118-index.htm |
| 2019-12-16 | Jane Huang | CMO, Hematology | Sell | 100.00 | 173.59 | 17,359.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000135/0001651308-19-000135-index.htm |
| 2020-01-21 | Jane Huang | CMO, Hematology | Sell | 87.00 | 172.34 | 14,993.58 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000009/0001651308-20-000009-index.htm |
| 2020-02-18 | Jane Huang | CMO, Hematology | Sell | 321.00 | 171.14 | 54,934.78 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000015/0001651308-20-000015-index.htm |
| 2020-04-16 | Jane Huang | CMO, Hematology | Sell | 1,500.00 | 160.00 | 240,000.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000043/0001651308-20-000043-index.htm |
| 2020-04-29 | Jane Huang | CMO, Hematology | Sell | 1,500.00 | 162.30 | 243,450.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000044/0001651308-20-000044-index.htm |
| 2020-05-29 | Jane Huang | CMO, Hematology | Sell | 431.00 | 165.12 | 71,168.10 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000061/0001651308-20-000061-index.htm |
| 2020-06-08 | Jane Huang | CMO, Hematology | Sell | 631.00 | 170.84 | 107,800.04 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000065/0001651308-20-000065-index.htm |
| 2020-06-26 | Jane Huang | CMO, Hematology | Sell | 700.00 | 200.30 | 140,207.97 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000087/0001651308-20-000087-index.htm |
| 2020-06-29 | Jane Huang | CMO, Hematology | Sell | 435.00 | 192.46 | 83,720.10 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000087/0001651308-20-000087-index.htm |
| 2020-06-29 | Jane Huang | CMO, Hematology | Sell | 100.00 | 193.56 | 19,356.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000087/0001651308-20-000087-index.htm |
| 2020-07-07 | Jane Huang | CMO, Hematology | Sell | 3,921.00 | 200.00 | 784,200.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000094/0001651308-20-000094-index.htm |
| 2020-07-29 | Jane Huang | CMO, Hematology | Sell | 399.00 | 213.56 | 85,210.16 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000106/0001651308-20-000106-index.htm |
| 2020-08-28 | Jane Huang | CMO, Hematology | Sell | 300.00 | 244.93 | 73,478.01 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000145/0001651308-20-000145-index.htm |
| 2020-09-03 | Jane Huang | CMO, Hematology | Sell | 217.00 | 235.21 | 51,041.29 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000147/0001651308-20-000147-index.htm |
| 2020-09-29 | Jane Huang | CMO, Hematology | Sell | 102.00 | 283.83 | 28,950.34 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000182/0001651308-20-000182-index.htm |
| 2020-10-29 | Jane Huang | CMO, Hematology | Sell | 100.00 | 301.51 | 30,151.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000198/0001651308-20-000198-index.htm |
| 2019-12-17 | JOHN OYLER | Chief Executive Officer | Sell | 1,958.00 | 165.61 | 324,262.81 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000136/0001651308-19-000136-index.htm |
| 2020-05-01 | JOHN OYLER | Chief Executive Officer | Sell | 474.00 | 141.00 | 66,834.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000046/0001651308-20-000046-index.htm |
| 2020-06-10 | JOHN OYLER | Chief Executive Officer | Sell | 900.00 | 175.07 | 157,563.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000068/0001651308-20-000068-index.htm |
| 2020-06-24 | JOHN OYLER | Chief Executive Officer | Sell | 1,725.00 | 189.42 | 326,745.02 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000086/0001651308-20-000086-index.htm |
| 2020-06-29 | JOHN OYLER | Chief Executive Officer | Sell | 35.00 | 193.68 | 6,778.80 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000089/0001651308-20-000089-index.htm |
| 2020-07-01 | JOHN OYLER | Chief Executive Officer | Sell | 1,800.00 | 192.08 | 345,751.56 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000089/0001651308-20-000089-index.htm |
| 2020-07-06 | JOHN OYLER | Chief Executive Officer | Sell | 2,561.00 | 198.32 | 507,901.11 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000093/0001651308-20-000093-index.htm |
| 2020-07-07 | JOHN OYLER | Chief Executive Officer | Sell | 8,318.00 | 199.88 | 1,662,566.90 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000093/0001651308-20-000093-index.htm |
| 2020-07-08 | JOHN OYLER | Chief Executive Officer | Sell | 2,854.00 | 203.81 | 581,680.30 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000093/0001651308-20-000093-index.htm |
| 2020-07-20 | JOHN OYLER | Chief Executive Officer | Sell | 200.00 | 254.23 | 50,846.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000104/0001651308-20-000104-index.htm |
| 2020-07-21 | JOHN OYLER | Chief Executive Officer | Sell | 1,300.00 | 255.53 | 332,194.72 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000104/0001651308-20-000104-index.htm |
| 2020-07-22 | JOHN OYLER | Chief Executive Officer | Sell | 100.00 | 248.00 | 24,800.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000105/0001651308-20-000105-index.htm |
| 2020-08-03 | JOHN OYLER | Chief Executive Officer | Sell | 300.00 | 225.08 | 67,524.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000108/0001651308-20-000108-index.htm |
| 2020-08-04 | JOHN OYLER | Chief Executive Officer | Sell | 100.00 | 226.00 | 22,600.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000108/0001651308-20-000108-index.htm |
| 2020-08-05 | JOHN OYLER | Chief Executive Officer | Sell | 621.00 | 227.00 | 140,969.86 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000110/0001651308-20-000110-index.htm |
| 2020-08-12 | JOHN OYLER | Chief Executive Officer | Sell | 1,200.00 | 214.00 | 256,803.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000122/0001651308-20-000122-index.htm |
| 2020-08-13 | JOHN OYLER | Chief Executive Officer | Sell | 1,903.00 | 216.10 | 411,245.91 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000122/0001651308-20-000122-index.htm |
| 2020-08-14 | JOHN OYLER | Chief Executive Officer | Sell | 300.00 | 214.06 | 64,218.99 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000122/0001651308-20-000122-index.htm |
| 2020-08-19 | JOHN OYLER | Chief Executive Officer | Sell | 1,300.00 | 237.04 | 308,154.73 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000125/0001651308-20-000125-index.htm |
| 2020-08-20 | JOHN OYLER | Chief Executive Officer | Sell | 4,679.00 | 237.44 | 1,110,971.93 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000125/0001651308-20-000125-index.htm |
| 2020-08-21 | JOHN OYLER | Chief Executive Officer | Sell | 694.00 | 243.48 | 168,976.09 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000125/0001651308-20-000125-index.htm |
| 2020-08-31 | JOHN OYLER | Chief Executive Officer | Sell | 42.00 | 242.81 | 10,198.02 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000146/0001651308-20-000146-index.htm |
| 2020-09-01 | JOHN OYLER | Chief Executive Officer | Sell | 900.00 | 239.63 | 215,665.02 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000146/0001651308-20-000146-index.htm |
| 2020-09-02 | JOHN OYLER | Chief Executive Officer | Sell | 2,016.00 | 234.78 | 473,307.81 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000146/0001651308-20-000146-index.htm |
| 2020-09-14 | JOHN OYLER | Chief Executive Officer | Sell | 170.00 | 252.53 | 42,930.30 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000153/0001651308-20-000153-index.htm |
| 2020-09-15 | JOHN OYLER | Chief Executive Officer | Sell | 266.00 | 257.87 | 68,593.42 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000153/0001651308-20-000153-index.htm |
| 2020-09-16 | JOHN OYLER | Chief Executive Officer | Sell | 723.00 | 257.97 | 186,512.89 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000153/0001651308-20-000153-index.htm |
| 2020-09-28 | JOHN OYLER | Chief Executive Officer | Sell | 700.00 | 282.87 | 198,009.98 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000180/0001651308-20-000180-index.htm |
| 2020-09-29 | JOHN OYLER | Chief Executive Officer | Sell | 400.00 | 283.80 | 113,521.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000180/0001651308-20-000180-index.htm |
| 2019-11-04 | Timothy Yung-Cheng Chen | Director | Sell | 200.00 | 192.06 | 38,411.26 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000104/0001651308-19-000104-index.htm |
| 2019-11-04 | Timothy Yung-Cheng Chen | Director | Sell | 100.00 | 192.18 | 19,218.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000104/0001651308-19-000104-index.htm |
| 2020-08-10 | Timothy Yung-Cheng Chen | Director | Sell | 300.00 | 216.57 | 64,971.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000121/0001651308-20-000121-index.htm |
| 2020-08-11 | Timothy Yung-Cheng Chen | Director | Sell | 203.00 | 214.23 | 43,489.48 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000121/0001651308-20-000121-index.htm |
| 2020-08-12 | Timothy Yung-Cheng Chen | Director | Sell | 2,897.00 | 212.00 | 614,164.87 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000121/0001651308-20-000121-index.htm |
| 2019-11-01 | Xiaobin Wu | President & GM China | Sell | 1,000.00 | 180.00 | 180,000.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000102/0001651308-19-000102-index.htm |
| 2019-11-15 | Xiaobin Wu | President & GM China | Sell | 1,000.00 | 202.05 | 202,050.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000116/0001651308-19-000116-index.htm |
| 2020-05-01 | Xiaobin Wu | President & GM China | Sell | 245.00 | 141.00 | 34,545.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000045/0001651308-20-000045-index.htm |
| 2020-06-08 | Xiaobin Wu | President & GM China | Sell | 475.00 | 171.98 | 81,690.55 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000066/0001651308-20-000066-index.htm |
| 2020-07-13 | Xiaobin Wu | President & GM China | Sell | 3,000.00 | 220.00 | 660,000.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000098/0001651308-20-000098-index.htm |
| 2020-07-15 | Xiaobin Wu | President & GM China | Sell | 200.00 | 246.10 | 49,220.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000098/0001651308-20-000098-index.htm |
| 2020-07-17 | Xiaobin Wu | President & GM China | Sell | 400.00 | 250.04 | 100,015.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000102/0001651308-20-000102-index.htm |
| 2020-07-20 | Xiaobin Wu | President & GM China | Sell | 2,600.00 | 250.16 | 650,407.42 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000102/0001651308-20-000102-index.htm |
| 2020-09-17 | Xiaobin Wu | President & GM China | Sell | 500.00 | 261.23 | 130,615.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000161/0001651308-20-000161-index.htm |
| 2020-09-25 | Xiaobin Wu | President & GM China | Sell | 4,000.00 | 280.35 | 1,121,406.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000175/0001651308-20-000175-index.htm |
| 2020-10-05 | Xiaobin Wu | President & GM China | Sell | 4,000.00 | 300.00 | 1,200,000.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000195/0001651308-20-000195-index.htm |
| 2019-11-01 | Xiaodong Wang | Director | Sell | 1,000.00 | 170.00 | 170,000.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000103/0001651308-19-000103-index.htm |
| 2019-11-04 | Xiaodong Wang | Director | Sell | 1,000.00 | 190.00 | 190,000.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000103/0001651308-19-000103-index.htm |
| 2019-11-15 | Xiaodong Wang | Director | Sell | 1,496.00 | 202.05 | 302,266.80 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000117/0001651308-19-000117-index.htm |
| 2020-03-04 | Xiaodong Wang | Director | Sell | 201.00 | 158.63 | 31,884.35 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000022/0001651308-20-000022-index.htm |
| 2020-06-08 | Xiaodong Wang | Director | Sell | 200.00 | 172.46 | 34,492.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000064/0001651308-20-000064-index.htm |
| 2020-06-22 | Xiaodong Wang | Director | Sell | 180.00 | 183.38 | 33,008.99 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000085/0001651308-20-000085-index.htm |
| 2020-06-23 | Xiaodong Wang | Director | Sell | 700.00 | 187.36 | 131,154.03 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000085/0001651308-20-000085-index.htm |
| 2020-07-01 | Xiaodong Wang | Director | Sell | 457.00 | 192.31 | 87,887.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000092/0001651308-20-000092-index.htm |
| 2020-07-07 | Xiaodong Wang | Director | Sell | 6,000.00 | 200.00 | 1,200,000.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000095/0001651308-20-000095-index.htm |
| 2020-07-20 | Xiaodong Wang | Director | Sell | 1,111.00 | 253.49 | 281,631.72 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000103/0001651308-20-000103-index.htm |
| 2020-07-20 | Xiaodong Wang | Director | Sell | 1,379.00 | 253.59 | 349,703.09 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000103/0001651308-20-000103-index.htm |
| 2020-08-10 | Xiaodong Wang | Director | Sell | 406.00 | 216.70 | 87,981.66 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000120/0001651308-20-000120-index.htm |
| 2020-09-17 | Xiaodong Wang | Director | Sell | 84.00 | 261.13 | 21,934.50 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000162/0001651308-20-000162-index.htm |
| 2020-09-25 | Xiaodong Wang | Director | Sell | 620.00 | 281.34 | 174,433.40 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000176/0001651308-20-000176-index.htm |
| 2020-10-05 | Xiaodong Wang | Director | Sell | 5,000.00 | 300.00 | 1,500,000.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000196/0001651308-20-000196-index.htm |
| 2020-10-16 | Xiaodong Wang | Director | Sell | 5,000.00 | 320.00 | 1,600,000.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000197/0001651308-20-000197-index.htm |
| 2019-11-18 | Jane Huang | CMO, Hematology | Sell | 95.00 | 195.82 | 18,602.90 | 100.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000118/0001651308-19-000118-index.htm |
| 2019-12-16 | Jane Huang | CMO, Hematology | Sell | 100.00 | 172.13 | 17,213.00 | 100.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000135/0001651308-19-000135-index.htm |
| 2020-06-29 | Jane Huang | CMO, Hematology | Sell | 198.00 | 192.72 | 38,157.61 | 100.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000087/0001651308-20-000087-index.htm |
| 2020-10-29 | Jane Huang | CMO, Hematology | Sell | 139.00 | 300.70 | 41,797.74 | 100.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000198/0001651308-20-000198-index.htm |
| 2020-07-22 | JOHN OYLER | Chief Executive Officer | Sell | 354.00 | 246.99 | 87,433.89 | 100.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000105/0001651308-20-000105-index.htm |
| 2020-08-04 | JOHN OYLER | Chief Executive Officer | Sell | 300.00 | 225.02 | 67,506.99 | 100.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000108/0001651308-20-000108-index.htm |
| 2019-11-04 | Timothy Yung-Cheng Chen | Director | Sell | 1,306.00 | 191.32 | 249,861.96 | 100.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000104/0001651308-19-000104-index.htm |
| 2020-05-29 | Jane Huang | CMO, Hematology | Sell | 500.00 | 162.63 | 81,315.80 | 1,000.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000061/0001651308-20-000061-index.htm |
| 2020-08-28 | Jane Huang | CMO, Hematology | Sell | 1,000.00 | 242.41 | 242,413.00 | 1,000.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000145/0001651308-20-000145-index.htm |
| 2020-09-29 | Jane Huang | CMO, Hematology | Sell | 468.00 | 281.75 | 131,859.14 | 102.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000182/0001651308-20-000182-index.htm |
| 2020-07-15 | BROS. ADVISORS LP BAKER | Director | Buy | 994,276.00 | 14.23 | 14,149,342.90 | 1,021,851.00 | https://www.sec.gov/Archives/edgar/data/1651308/000163859920000663/0001638599-20-000663-index.htm |
| 2020-09-16 | JOHN OYLER | Chief Executive Officer | Sell | 2,800.00 | 255.88 | 716,476.04 | 1,023.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000153/0001651308-20-000153-index.htm |
| 2020-09-14 | Howard Liang | CFO & Chief Strategy Officer | Sell | 2,181.00 | 251.95 | 549,511.67 | 103.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000152/0001651308-20-000152-index.htm |
| 2020-09-14 | JOHN OYLER | Chief Executive Officer | Sell | 7,116.00 | 249.73 | 1,777,102.16 | 10,523.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000153/0001651308-20-000153-index.htm |
| 2020-08-20 | JOHN OYLER | Chief Executive Officer | Sell | 4,798.00 | 234.45 | 1,124,895.42 | 10,625.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000125/0001651308-20-000125-index.htm |
| 2020-10-05 | Howard Liang | CFO & Chief Strategy Officer | Sell | 500.00 | 296.47 | 148,237.00 | 10,700.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000194/0001651308-20-000194-index.htm |
| 2020-08-04 | JOHN OYLER | Chief Executive Officer | Sell | 3,025.00 | 218.69 | 661,546.33 | 10,706.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000108/0001651308-20-000108-index.htm |
| 2020-08-10 | Timothy Yung-Cheng Chen | Director | Sell | 400.00 | 213.25 | 85,301.00 | 1,100.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000121/0001651308-20-000121-index.htm |
| 2020-08-12 | JOHN OYLER | Chief Executive Officer | Sell | 3,701.00 | 211.43 | 782,499.47 | 11,004.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000122/0001651308-20-000122-index.htm |
| 2020-07-20 | Xiaodong Wang | Director | Sell | 1,902.00 | 252.57 | 480,383.00 | 1,111.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000103/0001651308-20-000103-index.htm |
| 2020-10-05 | Howard Liang | CFO & Chief Strategy Officer | Sell | 568.00 | 295.73 | 167,972.82 | 11,200.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000194/0001651308-20-000194-index.htm |
| 2020-08-13 | JOHN OYLER | Chief Executive Officer | Sell | 800.00 | 213.56 | 170,846.00 | 11,231.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000122/0001651308-20-000122-index.htm |
| 2020-08-31 | JOHN OYLER | Chief Executive Officer | Sell | 600.00 | 239.09 | 143,452.02 | 11,261.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000146/0001651308-20-000146-index.htm |
| 2020-06-29 | JOHN OYLER | Chief Executive Officer | Sell | 300.00 | 191.56 | 57,468.00 | 1,135.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000089/0001651308-20-000089-index.htm |
| 2020-07-20 | Xiaodong Wang | Director | Sell | 500.00 | 249.78 | 124,890.00 | 11,500.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000103/0001651308-20-000103-index.htm |
| 2020-07-08 | JOHN OYLER | Chief Executive Officer | Sell | 2,900.00 | 200.55 | 581,597.03 | 11,529.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000093/0001651308-20-000093-index.htm |
| 2020-08-05 | JOHN OYLER | Chief Executive Officer | Sell | 3,600.00 | 221.32 | 796,768.92 | 11,654.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000110/0001651308-20-000110-index.htm |
| 2020-09-02 | JOHN OYLER | Chief Executive Officer | Sell | 610.00 | 228.92 | 139,643.03 | 11,694.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000146/0001651308-20-000146-index.htm |
| 2020-10-05 | Howard Liang | CFO & Chief Strategy Officer | Sell | 1,415.00 | 294.92 | 417,313.50 | 11,768.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000194/0001651308-20-000194-index.htm |
| 2020-08-31 | JOHN OYLER | Chief Executive Officer | Sell | 1,100.00 | 237.82 | 261,599.03 | 11,861.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000146/0001651308-20-000146-index.htm |
| 2020-09-14 | Howard Liang | CFO & Chief Strategy Officer | Sell | 1,681.00 | 248.93 | 418,453.85 | 11,919.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000152/0001651308-20-000152-index.htm |
| 2020-06-29 | Jane Huang | CMO, Hematology | Sell | 300.00 | 187.91 | 56,373.00 | 1,200.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000087/0001651308-20-000087-index.htm |
| 2020-08-12 | JOHN OYLER | Chief Executive Officer | Sell | 7,482.00 | 213.36 | 1,596,381.97 | 1,200.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000122/0001651308-20-000122-index.htm |
| 2020-08-13 | JOHN OYLER | Chief Executive Officer | Sell | 1,731.00 | 211.93 | 366,854.12 | 12,031.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000122/0001651308-20-000122-index.htm |
| 2020-08-10 | Xiaodong Wang | Director | Sell | 100.00 | 210.59 | 21,059.00 | 1,206.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000120/0001651308-20-000120-index.htm |
| 2020-09-02 | JOHN OYLER | Chief Executive Officer | Sell | 1,802.00 | 228.08 | 410,994.75 | 12,304.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000146/0001651308-20-000146-index.htm |
| 2020-08-19 | JOHN OYLER | Chief Executive Officer | Sell | 9,741.00 | 234.24 | 2,281,766.91 | 12,321.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000125/0001651308-20-000125-index.htm |
| 2020-07-22 | JOHN OYLER | Chief Executive Officer | Sell | 4,612.00 | 237.61 | 1,095,875.77 | 12,800.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000105/0001651308-20-000105-index.htm |
| 2019-11-18 | Jane Huang | CMO, Hematology | Sell | 200.00 | 192.24 | 38,448.00 | 1,300.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000118/0001651308-19-000118-index.htm |
| 2020-09-29 | Jane Huang | CMO, Hematology | Sell | 200.00 | 274.42 | 54,884.00 | 1,300.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000182/0001651308-20-000182-index.htm |
| 2020-07-21 | JOHN OYLER | Chief Executive Officer | Sell | 3,594.00 | 254.29 | 913,913.59 | 1,300.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000104/0001651308-20-000104-index.htm |
| 2020-08-19 | JOHN OYLER | Chief Executive Officer | Sell | 4,800.00 | 236.32 | 1,134,328.32 | 1,300.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000125/0001651308-20-000125-index.htm |
| 2020-08-10 | Xiaodong Wang | Director | Sell | 1,194.00 | 209.91 | 250,631.70 | 1,306.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000120/0001651308-20-000120-index.htm |
| 2020-10-05 | Howard Liang | CFO & Chief Strategy Officer | Sell | 817.00 | 293.26 | 239,595.54 | 13,183.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000194/0001651308-20-000194-index.htm |
| 2020-07-21 | JOHN OYLER | Chief Executive Officer | Sell | 5,751.00 | 251.62 | 1,447,074.10 | 13,290.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000104/0001651308-20-000104-index.htm |
| 2020-09-01 | JOHN OYLER | Chief Executive Officer | Sell | 2,959.00 | 231.92 | 686,250.39 | 13,370.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000146/0001651308-20-000146-index.htm |
| 2020-09-14 | Howard Liang | CFO & Chief Strategy Officer | Sell | 400.00 | 247.46 | 98,985.00 | 13,600.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000152/0001651308-20-000152-index.htm |
| 2020-09-15 | JOHN OYLER | Chief Executive Officer | Sell | 4,642.00 | 255.64 | 1,186,670.67 | 1,366.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000153/0001651308-20-000153-index.htm |
| 2020-08-04 | JOHN OYLER | Chief Executive Officer | Sell | 1,369.00 | 217.73 | 298,067.58 | 13,731.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000108/0001651308-20-000108-index.htm |
| 2020-08-13 | JOHN OYLER | Chief Executive Officer | Sell | 681.00 | 211.01 | 143,697.47 | 13,762.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000122/0001651308-20-000122-index.htm |
| 2020-07-20 | Xiaodong Wang | Director | Sell | 2,039.00 | 252.61 | 515,075.26 | 1,379.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000103/0001651308-20-000103-index.htm |
| 2020-07-07 | JOHN OYLER | Chief Executive Officer | Sell | 1,501.00 | 197.80 | 296,903.20 | 13,792.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000093/0001651308-20-000093-index.htm |
| 2019-12-16 | Jane Huang | CMO, Hematology | Sell | 100.00 | 160.07 | 16,007.00 | 1,400.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000135/0001651308-19-000135-index.htm |
| 2020-06-26 | Jane Huang | CMO, Hematology | Sell | 679.00 | 200.27 | 135,984.62 | 1,400.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000087/0001651308-20-000087-index.htm |
| 2020-09-14 | Howard Liang | CFO & Chief Strategy Officer | Buy | 14,000.00 | 6.50 | 91,000.00 | 14,000.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000152/0001651308-20-000152-index.htm |
| 2020-10-05 | Howard Liang | CFO & Chief Strategy Officer | Buy | 14,000.00 | 6.50 | 91,000.00 | 14,000.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000194/0001651308-20-000194-index.htm |
| 2019-11-04 | Timothy Yung-Cheng Chen | Director | Sell | 1,394.00 | 190.34 | 265,337.72 | 1,406.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000104/0001651308-19-000104-index.htm |
| 2020-09-02 | JOHN OYLER | Chief Executive Officer | Sell | 8,019.00 | 226.97 | 1,820,064.41 | 14,106.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000146/0001651308-20-000146-index.htm |
| 2020-06-23 | JOHN OYLER | Chief Executive Officer | Sell | 410.00 | 188.43 | 77,257.98 | 14,381.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000086/0001651308-20-000086-index.htm |
| 2020-07-08 | JOHN OYLER | Chief Executive Officer | Sell | 1,800.00 | 199.26 | 358,672.32 | 14,429.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000093/0001651308-20-000093-index.htm |
| 2020-07-20 | JOHN OYLER | Chief Executive Officer | Sell | 4,032.00 | 251.41 | 1,013,704.07 | 14,493.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000104/0001651308-20-000104-index.htm |
| 2019-11-18 | Howard Liang | CFO & Chief Strategy Officer | Sell | 6,944.00 | 193.60 | 1,344,334.10 | 14,589.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000119/0001651308-19-000119-index.htm |
| 2020-08-12 | JOHN OYLER | Chief Executive Officer | Sell | 4,015.00 | 210.37 | 844,621.50 | 14,705.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000122/0001651308-20-000122-index.htm |
| 2020-06-23 | JOHN OYLER | Chief Executive Officer | Sell | 7,438.00 | 187.46 | 1,394,334.92 | 14,791.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000086/0001651308-20-000086-index.htm |
| 2019-11-14 | Xiaodong Wang | Director | Sell | 100.00 | 196.87 | 19,687.00 | 1,496.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000117/0001651308-19-000117-index.htm |
| 2019-11-18 | Jane Huang | CMO, Hematology | Buy | 1,500.00 | 29.49 | 44,235.00 | 1,500.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000118/0001651308-19-000118-index.htm |
| 2019-12-16 | Jane Huang | CMO, Hematology | Buy | 1,500.00 | 29.49 | 44,235.00 | 1,500.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000135/0001651308-19-000135-index.htm |
| 2020-01-21 | Jane Huang | CMO, Hematology | Buy | 1,500.00 | 29.49 | 44,235.00 | 1,500.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000009/0001651308-20-000009-index.htm |
| 2020-02-18 | Jane Huang | CMO, Hematology | Buy | 1,500.00 | 29.49 | 44,235.00 | 1,500.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000015/0001651308-20-000015-index.htm |
| 2020-04-16 | Jane Huang | CMO, Hematology | Buy | 1,500.00 | 29.49 | 44,235.00 | 1,500.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000043/0001651308-20-000043-index.htm |
| 2020-04-29 | Jane Huang | CMO, Hematology | Buy | 1,500.00 | 29.49 | 44,235.00 | 1,500.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000044/0001651308-20-000044-index.htm |
| 2020-05-29 | Jane Huang | CMO, Hematology | Buy | 1,500.00 | 29.49 | 44,235.00 | 1,500.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000061/0001651308-20-000061-index.htm |
| 2020-06-29 | Jane Huang | CMO, Hematology | Buy | 1,500.00 | 29.49 | 44,235.00 | 1,500.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000087/0001651308-20-000087-index.htm |
| 2020-07-29 | Jane Huang | CMO, Hematology | Buy | 1,500.00 | 29.49 | 44,235.00 | 1,500.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000106/0001651308-20-000106-index.htm |
| 2020-09-29 | Jane Huang | CMO, Hematology | Buy | 1,500.00 | 29.49 | 44,235.00 | 1,500.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000182/0001651308-20-000182-index.htm |
| 2020-10-29 | Jane Huang | CMO, Hematology | Buy | 1,500.00 | 29.49 | 44,235.00 | 1,500.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000198/0001651308-20-000198-index.htm |
| 2020-08-10 | Timothy Yung-Cheng Chen | Director | Sell | 700.00 | 212.34 | 148,640.73 | 1,500.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000121/0001651308-20-000121-index.htm |
| 2020-08-04 | JOHN OYLER | Chief Executive Officer | Sell | 283.00 | 216.63 | 61,304.90 | 15,100.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000108/0001651308-20-000108-index.htm |
| 2020-06-17 | Xiaobin Wu | President & GM China | Buy | 134,147.00 | 1,514,562.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000074/0001651308-20-000074-index.htm | ||
| 2020-08-05 | JOHN OYLER | Chief Executive Officer | Sell | 1,300.00 | 220.16 | 286,201.50 | 15,254.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000110/0001651308-20-000110-index.htm |
| 2020-07-07 | JOHN OYLER | Chief Executive Officer | Sell | 3,730.00 | 196.82 | 734,125.92 | 15,293.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000093/0001651308-20-000093-index.htm |
| 2020-08-20 | JOHN OYLER | Chief Executive Officer | Sell | 600.00 | 233.13 | 139,875.18 | 15,423.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000125/0001651308-20-000125-index.htm |
| 2019-11-04 | Jane Huang | CMO, Hematology | Sell | 12,523.00 | 190.00 | 2,379,398.80 | 15,808.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000105/0001651308-19-000105-index.htm |
| 2019-11-14 | Xiaodong Wang | Director | Sell | 300.00 | 195.86 | 58,757.01 | 1,596.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000117/0001651308-19-000117-index.htm |
| 2020-06-08 | Xiaobin Wu | President & GM China | Sell | 1,200.00 | 170.02 | 204,022.08 | 1,600.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000066/0001651308-20-000066-index.htm |
| 2020-08-20 | JOHN OYLER | Chief Executive Officer | Sell | 2,000.00 | 232.34 | 464,678.20 | 16,023.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000125/0001651308-20-000125-index.htm |
| 2020-08-21 | JOHN OYLER | Chief Executive Officer | Sell | 10,997.00 | 239.66 | 2,635,539.92 | 16,120.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000125/0001651308-20-000125-index.htm |
| 2020-07-08 | JOHN OYLER | Chief Executive Officer | Sell | 700.00 | 197.98 | 138,584.60 | 16,229.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000093/0001651308-20-000093-index.htm |
| 2020-09-01 | JOHN OYLER | Chief Executive Officer | Sell | 3,945.00 | 230.87 | 910,772.68 | 16,329.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000146/0001651308-20-000146-index.htm |
| 2020-08-05 | JOHN OYLER | Chief Executive Officer | Sell | 700.00 | 218.96 | 153,272.00 | 16,554.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000110/0001651308-20-000110-index.htm |
| 2020-07-06 | JOHN OYLER | Chief Executive Officer | Sell | 800.00 | 195.43 | 156,347.04 | 16,562.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000093/0001651308-20-000093-index.htm |
| 2020-07-08 | JOHN OYLER | Chief Executive Officer | Sell | 600.00 | 196.51 | 117,907.98 | 16,929.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000093/0001651308-20-000093-index.htm |
| 2020-09-16 | JOHN OYLER | Chief Executive Officer | Sell | 10,312.00 | 253.71 | 2,616,255.46 | 16,963.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000153/0001651308-20-000153-index.htm |
| 2020-07-29 | Jane Huang | CMO, Hematology | Sell | 1,301.00 | 208.35 | 271,066.86 | 1,699.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000106/0001651308-20-000106-index.htm |
| 2020-09-14 | JOHN OYLER | Chief Executive Officer | Sell | 3,476.00 | 251.90 | 875,605.79 | 170.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000153/0001651308-20-000153-index.htm |
| 2020-09-29 | JOHN OYLER | Chief Executive Officer | Sell | 3,831.00 | 280.30 | 1,073,814.36 | 17,072.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000180/0001651308-20-000180-index.htm |
| 2020-06-17 | Howard Liang | CFO & Chief Strategy Officer | Buy | 55,887.00 | 172,315.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000075/0001651308-20-000075-index.htm | ||
| 2020-06-24 | JOHN OYLER | Chief Executive Officer | Sell | 3,800.00 | 188.20 | 715,162.66 | 1,725.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000086/0001651308-20-000086-index.htm |
| 2020-07-22 | JOHN OYLER | Chief Executive Officer | Sell | 4,200.00 | 236.14 | 991,788.00 | 17,412.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000105/0001651308-20-000105-index.htm |
| 2020-09-14 | JOHN OYLER | Chief Executive Officer | Sell | 1,500.00 | 248.56 | 372,842.25 | 17,639.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000153/0001651308-20-000153-index.htm |
| 2020-05-01 | Xiaobin Wu | President & GM China | Sell | 5,255.00 | 140.96 | 740,744.80 | 1,769.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000045/0001651308-20-000045-index.htm |
| 2020-06-22 | Xiaodong Wang | Director | Sell | 800.00 | 182.52 | 146,016.48 | 180.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000085/0001651308-20-000085-index.htm |
| 2020-07-01 | JOHN OYLER | Chief Executive Officer | Sell | 2,016.00 | 191.10 | 385,264.66 | 1,800.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000089/0001651308-20-000089-index.htm |
| 2020-08-14 | JOHN OYLER | Chief Executive Officer | Sell | 1,790.00 | 211.63 | 378,824.86 | 1,800.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000122/0001651308-20-000122-index.htm |
| 2020-08-20 | JOHN OYLER | Chief Executive Officer | Sell | 2,500.00 | 231.15 | 577,881.00 | 18,023.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000125/0001651308-20-000125-index.htm |
| 2020-08-18 | AMGEN INC | 10% Share Holder | Buy | 40,000.00 | 230.18 | 9,207,188.00 | 18,213,065.00 | https://www.sec.gov/Archives/edgar/data/1651308/000089924320023107/0000899243-20-023107-index.htm |
| 2020-08-19 | AMGEN INC | 10% Share Holder | Buy | 64,176.00 | 234.88 | 15,073,453.52 | 18,277,241.00 | https://www.sec.gov/Archives/edgar/data/1651308/000089924320023107/0000899243-20-023107-index.htm |
| 2020-08-20 | AMGEN INC | 10% Share Holder | Buy | 64,176.00 | 234.99 | 15,080,981.36 | 18,341,417.00 | https://www.sec.gov/Archives/edgar/data/1651308/000089924320023107/0000899243-20-023107-index.htm |
| 2020-08-21 | AMGEN INC | 10% Share Holder | Buy | 64,176.00 | 230.18 | 14,772,012.43 | 18,405,593.00 | https://www.sec.gov/Archives/edgar/data/1651308/000089924320023319/0000899243-20-023319-index.htm |
| 2020-08-24 | AMGEN INC | 10% Share Holder | Buy | 59,390.00 | 239.10 | 14,199,905.50 | 18,464,983.00 | https://www.sec.gov/Archives/edgar/data/1651308/000089924320023319/0000899243-20-023319-index.htm |
| 2020-08-25 | AMGEN INC | 10% Share Holder | Buy | 59,390.00 | 248.49 | 14,757,577.60 | 18,524,373.00 | https://www.sec.gov/Archives/edgar/data/1651308/000089924320023386/0000899243-20-023386-index.htm |
| 2020-07-20 | JOHN OYLER | Chief Executive Officer | Sell | 7,326.00 | 250.51 | 1,835,211.35 | 18,525.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000104/0001651308-20-000104-index.htm |
| 2020-08-12 | JOHN OYLER | Chief Executive Officer | Sell | 1,100.00 | 209.38 | 230,318.88 | 18,720.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000122/0001651308-20-000122-index.htm |
| 2020-09-15 | JOHN OYLER | Chief Executive Officer | Sell | 5,339.00 | 253.80 | 1,355,032.86 | 18,807.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000153/0001651308-20-000153-index.htm |
| 2020-07-15 | BROS. ADVISORS LP BAKER | Director | Buy | 13,589,904.00 | 14.23 | 193,395,205.84 | 18,840,379.00 | https://www.sec.gov/Archives/edgar/data/1651308/000163859920000663/0001638599-20-000663-index.htm |
| 2019-11-14 | Xiaodong Wang | Director | Sell | 1,900.00 | 195.14 | 370,773.98 | 1,896.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000117/0001651308-19-000117-index.htm |
| 2020-07-22 | JOHN OYLER | Chief Executive Officer | Sell | 1,900.00 | 242.62 | 460,984.84 | 1,900.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000105/0001651308-20-000105-index.htm |
| 2020-09-01 | JOHN OYLER | Chief Executive Officer | Sell | 647.00 | 237.27 | 153,510.52 | 1,900.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000146/0001651308-20-000146-index.htm |
| 2020-08-13 | JOHN OYLER | Chief Executive Officer | Sell | 5,585.00 | 215.30 | 1,202,464.46 | 1,903.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000122/0001651308-20-000122-index.htm |
| 2020-08-11 | Timothy Yung-Cheng Chen | Director | Buy | 1,903.00 | 31.59 | 60,115.77 | 1,903.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000121/0001651308-20-000121-index.htm |
| 2020-07-21 | JOHN OYLER | Chief Executive Officer | Sell | 1,612.00 | 250.49 | 403,790.04 | 19,041.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000104/0001651308-20-000104-index.htm |
| 2020-09-14 | JOHN OYLER | Chief Executive Officer | Sell | 600.00 | 247.01 | 148,206.24 | 19,139.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000153/0001651308-20-000153-index.htm |
| 2019-11-18 | Jane Huang | CMO, Hematology | Sell | 605.00 | 195.01 | 117,983.35 | 195.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000118/0001651308-19-000118-index.htm |
| 2019-12-17 | JOHN OYLER | Chief Executive Officer | Sell | 200.00 | 163.20 | 32,640.00 | 1,958.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000136/0001651308-19-000136-index.htm |
| 2020-03-04 | Xiaodong Wang | Director | Sell | 3,031.00 | 156.82 | 475,321.12 | 1,969.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000022/0001651308-20-000022-index.htm |
| 2019-12-16 | Jane Huang | CMO, Hematology | Sell | 200.00 | 170.73 | 34,145.00 | 200.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000135/0001651308-19-000135-index.htm |
| 2020-07-20 | JOHN OYLER | Chief Executive Officer | Sell | 6,948.00 | 253.67 | 1,762,528.34 | 200.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000104/0001651308-20-000104-index.htm |
| 2019-11-05 | Timothy Yung-Cheng Chen | Director | Sell | 208.00 | 190.32 | 39,587.18 | 200.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000104/0001651308-19-000104-index.htm |
| 2020-07-15 | Xiaobin Wu | President & GM China | Sell | 200.00 | 243.91 | 48,781.00 | 200.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000098/0001651308-20-000098-index.htm |
| 2020-06-08 | Xiaodong Wang | Director | Sell | 2,300.00 | 171.42 | 394,277.04 | 200.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000064/0001651308-20-000064-index.htm |
| 2020-08-28 | Jane Huang | CMO, Hematology | Sell | 200.00 | 240.86 | 48,172.00 | 2,000.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000145/0001651308-20-000145-index.htm |
| 2020-09-29 | JOHN OYLER | Chief Executive Officer | Sell | 4,236.00 | 282.05 | 1,194,759.99 | 2,009.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000180/0001651308-20-000180-index.htm |
| 2020-03-04 | Xiaodong Wang | Director | Sell | 1,768.00 | 157.51 | 278,475.74 | 201.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000022/0001651308-20-000022-index.htm |
| 2020-09-02 | JOHN OYLER | Chief Executive Officer | Sell | 3,018.00 | 234.28 | 707,062.47 | 2,016.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000146/0001651308-20-000146-index.htm |
| 2020-08-11 | Timothy Yung-Cheng Chen | Director | Sell | 700.00 | 213.59 | 149,512.51 | 203.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000121/0001651308-20-000121-index.htm |
| 2020-08-20 | JOHN OYLER | Chief Executive Officer | Sell | 1,000.00 | 230.16 | 230,158.00 | 20,523.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000125/0001651308-20-000125-index.htm |
| 2020-07-01 | Xiaodong Wang | Director | Sell | 2,100.00 | 190.46 | 399,956.97 | 2,057.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000092/0001651308-20-000092-index.htm |
| 2020-07-21 | JOHN OYLER | Chief Executive Officer | Sell | 1,350.00 | 249.05 | 336,218.99 | 20,653.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000104/0001651308-20-000104-index.htm |
| 2020-06-26 | Jane Huang | CMO, Hematology | Buy | 2,079.00 | 160.40 | 333,471.60 | 2,079.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000087/0001651308-20-000087-index.htm |
| 2020-09-29 | JOHN OYLER | Chief Executive Officer | Sell | 800.00 | 278.92 | 223,136.16 | 20,903.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000180/0001651308-20-000180-index.htm |
| 2020-09-03 | Jane Huang | CMO, Hematology | Sell | 1,000.00 | 232.25 | 232,246.90 | 2,128.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000147/0001651308-20-000147-index.htm |
| 2020-08-03 | JOHN OYLER | Chief Executive Officer | Sell | 2,876.00 | 220.42 | 633,919.58 | 21,394.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000108/0001651308-20-000108-index.htm |
| 2019-11-18 | Howard Liang | CFO & Chief Strategy Officer | Sell | 2,311.00 | 192.63 | 445,168.16 | 21,533.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000119/0001651308-19-000119-index.htm |
| 2019-12-17 | JOHN OYLER | Chief Executive Officer | Sell | 2,400.00 | 162.42 | 389,796.48 | 2,158.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000136/0001651308-19-000136-index.htm |
| 2020-07-22 | JOHN OYLER | Chief Executive Officer | Sell | 6,136.00 | 235.26 | 1,443,546.16 | 21,612.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000105/0001651308-20-000105-index.htm |
| 2020-10-05 | Howard Liang | CFO & Chief Strategy Officer | Sell | 2,831.00 | 302.11 | 855,260.10 | 2,169.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000194/0001651308-20-000194-index.htm |
| 2020-09-03 | Jane Huang | CMO, Hematology | Sell | 500.00 | 234.17 | 117,085.00 | 217.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000147/0001651308-20-000147-index.htm |
| 2020-09-29 | JOHN OYLER | Chief Executive Officer | Sell | 400.00 | 276.88 | 110,752.00 | 21,703.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000180/0001651308-20-000180-index.htm |
| 2020-08-28 | Jane Huang | CMO, Hematology | Sell | 800.00 | 240.15 | 192,121.28 | 2,200.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000145/0001651308-20-000145-index.htm |
| 2020-08-10 | Timothy Yung-Cheng Chen | Director | Buy | 2,200.00 | 31.59 | 69,498.00 | 2,200.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000121/0001651308-20-000121-index.htm |
| 2020-07-21 | JOHN OYLER | Chief Executive Officer | Sell | 4,410.00 | 248.12 | 1,094,201.26 | 22,003.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000104/0001651308-20-000104-index.htm |
| 2020-08-19 | JOHN OYLER | Chief Executive Officer | Sell | 4,403.00 | 233.35 | 1,027,421.12 | 22,062.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000125/0001651308-20-000125-index.htm |
| 2020-09-29 | JOHN OYLER | Chief Executive Officer | Sell | 200.00 | 274.42 | 54,884.00 | 22,103.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000180/0001651308-20-000180-index.htm |
| 2020-09-02 | JOHN OYLER | Chief Executive Officer | Sell | 4,482.00 | 226.07 | 1,013,257.84 | 22,125.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000146/0001651308-20-000146-index.htm |
| 2020-06-23 | JOHN OYLER | Chief Executive Officer | Sell | 4,922.00 | 186.63 | 918,568.74 | 22,229.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000086/0001651308-20-000086-index.htm |
| 2020-09-29 | JOHN OYLER | Chief Executive Officer | Sell | 550.00 | 274.08 | 150,744.00 | 22,303.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000180/0001651308-20-000180-index.htm |
| 2019-12-17 | JOHN OYLER | Chief Executive Officer | Sell | 16,965.00 | 160.60 | 2,724,572.21 | 22,773.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000136/0001651308-19-000136-index.htm |
| 2020-09-14 | Howard Liang | CFO & Chief Strategy Officer | Sell | 3,157.00 | 250.71 | 791,479.79 | 2,284.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000152/0001651308-20-000152-index.htm |
| 2020-09-29 | JOHN OYLER | Chief Executive Officer | Sell | 450.00 | 272.74 | 122,731.02 | 22,853.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000180/0001651308-20-000180-index.htm |
| 2019-11-05 | Timothy Yung-Cheng Chen | Director | Sell | 1,500.00 | 188.71 | 283,069.80 | 2,300.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000104/0001651308-19-000104-index.htm |
| 2020-09-28 | JOHN OYLER | Chief Executive Officer | Sell | 5,187.00 | 279.24 | 1,448,395.58 | 23,580.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000180/0001651308-20-000180-index.htm |
| 2020-07-15 | AMGEN INC | 10% Share Holder | Buy | 29,614,832.00 | 14.23 | 421,442,751.23 | 236,249,845.00 | https://www.sec.gov/Archives/edgar/data/1651308/000089924320019383/0000899243-20-019383-index.htm |
| 2019-11-18 | Howard Liang | CFO & Chief Strategy Officer | Sell | 1,156.00 | 191.80 | 221,723.69 | 23,844.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000119/0001651308-19-000119-index.htm |
| 2020-10-29 | Jane Huang | CMO, Hematology | Sell | 1,261.00 | 299.88 | 378,144.27 | 239.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000198/0001651308-20-000198-index.htm |
| 2020-09-15 | JOHN OYLER | Chief Executive Officer | Sell | 7,868.00 | 252.97 | 1,990,352.22 | 24,146.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000153/0001651308-20-000153-index.htm |
| 2020-08-03 | JOHN OYLER | Chief Executive Officer | Sell | 206.00 | 219.22 | 45,159.90 | 24,270.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000108/0001651308-20-000108-index.htm |
| 2020-08-03 | JOHN OYLER | Chief Executive Officer | Sell | 200.00 | 216.72 | 43,343.00 | 24,476.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000108/0001651308-20-000108-index.htm |
| 2020-05-01 | Xiaobin Wu | President & GM China | Sell | 300.00 | 143.17 | 42,951.99 | 245.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000045/0001651308-20-000045-index.htm |
| 2020-08-03 | JOHN OYLER | Chief Executive Officer | Sell | 400.00 | 214.99 | 85,994.88 | 24,676.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000108/0001651308-20-000108-index.htm |
| 2020-09-28 | JOHN OYLER | Chief Executive Officer | Sell | 21,080.00 | 280.26 | 5,907,882.91 | 2,500.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000180/0001651308-20-000180-index.htm |
| 2020-06-08 | Xiaodong Wang | Director | Sell | 3,500.00 | 170.48 | 596,685.60 | 2,500.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000064/0001651308-20-000064-index.htm |
| 2020-08-10 | Xiaodong Wang | Director | Sell | 1,500.00 | 208.91 | 313,363.95 | 2,500.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000120/0001651308-20-000120-index.htm |
| 2019-11-18 | Howard Liang | CFO & Chief Strategy Officer | Buy | 25,000.00 | 6.50 | 162,500.00 | 25,000.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000119/0001651308-19-000119-index.htm |
| 2020-08-03 | JOHN OYLER | Chief Executive Officer | Sell | 100.00 | 212.53 | 21,253.00 | 25,076.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000108/0001651308-20-000108-index.htm |
| 2020-09-01 | JOHN OYLER | Chief Executive Officer | Sell | 1,904.00 | 236.12 | 449,580.48 | 2,547.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000146/0001651308-20-000146-index.htm |
| 2020-07-06 | JOHN OYLER | Chief Executive Officer | Sell | 6,300.00 | 197.43 | 1,243,810.26 | 2,561.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000093/0001651308-20-000093-index.htm |
| 2020-07-20 | JOHN OYLER | Chief Executive Officer | Sell | 2,211.00 | 249.82 | 552,344.50 | 25,851.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000104/0001651308-20-000104-index.htm |
| 2020-08-04 | JOHN OYLER | Chief Executive Officer | Sell | 3,300.00 | 221.85 | 732,101.04 | 2,622.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000108/0001651308-20-000108-index.htm |
| 2020-08-19 | JOHN OYLER | Chief Executive Officer | Sell | 3,401.00 | 232.36 | 790,242.76 | 26,465.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000125/0001651308-20-000125-index.htm |
| 2020-09-15 | JOHN OYLER | Chief Executive Officer | Sell | 1,100.00 | 256.82 | 282,505.96 | 266.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000153/0001651308-20-000153-index.htm |
| 2020-09-02 | JOHN OYLER | Chief Executive Officer | Sell | 1,200.00 | 224.52 | 269,427.96 | 26,607.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000146/0001651308-20-000146-index.htm |
| 2020-08-03 | JOHN OYLER | Chief Executive Officer | Sell | 3,107.00 | 223.46 | 694,301.41 | 2,700.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000108/0001651308-20-000108-index.htm |
| 2020-08-21 | JOHN OYLER | Chief Executive Officer | Sell | 10,568.00 | 238.86 | 2,524,292.56 | 27,117.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000125/0001651308-20-000125-index.htm |
| 2020-06-23 | JOHN OYLER | Chief Executive Officer | Sell | 1,610.00 | 185.54 | 298,711.99 | 27,151.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000086/0001651308-20-000086-index.htm |
| 2019-11-04 | Timothy Yung-Cheng Chen | Director | Sell | 1,200.00 | 189.37 | 227,243.64 | 2,800.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000104/0001651308-19-000104-index.htm |
| 2020-07-20 | JOHN OYLER | Chief Executive Officer | Sell | 700.00 | 248.70 | 174,088.18 | 28,062.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000104/0001651308-20-000104-index.htm |
| 2019-11-04 | Jane Huang | CMO, Hematology | Sell | 4,569.00 | 189.08 | 863,921.14 | 28,331.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000105/0001651308-19-000105-index.htm |
| 2020-07-08 | JOHN OYLER | Chief Executive Officer | Sell | 3,834.00 | 202.37 | 775,895.01 | 2,854.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000093/0001651308-20-000093-index.htm |
| 2020-06-23 | JOHN OYLER | Chief Executive Officer | Sell | 690.00 | 184.56 | 127,348.40 | 28,761.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000086/0001651308-20-000086-index.htm |
| 2020-09-28 | JOHN OYLER | Chief Executive Officer | Sell | 2,233.00 | 278.50 | 621,900.55 | 28,767.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000180/0001651308-20-000180-index.htm |
| 2020-08-12 | Timothy Yung-Cheng Chen | Director | Buy | 2,897.00 | 31.59 | 91,516.23 | 2,897.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000121/0001651308-20-000121-index.htm |
| 2020-06-22 | JOHN OYLER | Chief Executive Officer | Sell | 3,095.00 | 183.72 | 568,600.71 | 29,451.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000086/0001651308-20-000086-index.htm |
| 2020-06-29 | Jane Huang | CMO, Hematology | Sell | 500.00 | 191.37 | 95,685.00 | 298.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000087/0001651308-20-000087-index.htm |
| 2020-10-05 | Howard Liang | CFO & Chief Strategy Officer | Sell | 1,869.00 | 303.24 | 566,757.06 | 300.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000194/0001651308-20-000194-index.htm |
| 2019-11-04 | Jane Huang | CMO, Hematology | Sell | 2,854.00 | 191.96 | 547,844.42 | 300.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000105/0001651308-19-000105-index.htm |
| 2020-08-28 | Jane Huang | CMO, Hematology | Sell | 700.00 | 243.49 | 170,442.02 | 300.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000145/0001651308-20-000145-index.htm |
| 2020-08-03 | JOHN OYLER | Chief Executive Officer | Sell | 2,400.00 | 224.23 | 538,150.08 | 300.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000108/0001651308-20-000108-index.htm |
| 2020-08-14 | JOHN OYLER | Chief Executive Officer | Sell | 1,500.00 | 212.99 | 319,484.40 | 300.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000122/0001651308-20-000122-index.htm |
| 2020-08-10 | Timothy Yung-Cheng Chen | Director | Sell | 300.00 | 215.47 | 64,641.00 | 300.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000121/0001651308-20-000121-index.htm |
| 2020-07-29 | Jane Huang | CMO, Hematology | Buy | 1,500.00 | 160.40 | 240,600.00 | 3,000.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000106/0001651308-20-000106-index.htm |
| 2020-08-28 | Jane Huang | CMO, Hematology | Buy | 3,000.00 | 29.49 | 88,470.00 | 3,000.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000145/0001651308-20-000145-index.htm |
| 2020-07-20 | Xiaodong Wang | Director | Sell | 687.00 | 251.34 | 172,668.31 | 3,013.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000103/0001651308-20-000103-index.htm |
| 2019-11-04 | Jane Huang | CMO, Hematology | Sell | 12,654.00 | 191.01 | 2,417,011.44 | 3,154.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000105/0001651308-19-000105-index.htm |
| 2020-06-22 | Xiaodong Wang | Director | Sell | 1,800.00 | 180.37 | 324,665.82 | 3,200.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000085/0001651308-20-000085-index.htm |
| 2020-09-15 | JOHN OYLER | Chief Executive Officer | Sell | 2,200.00 | 251.39 | 553,067.90 | 32,014.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000153/0001651308-20-000153-index.htm |
| 2020-02-18 | Jane Huang | CMO, Hematology | Sell | 1,179.00 | 170.01 | 200,445.21 | 321.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000015/0001651308-20-000015-index.htm |
| 2020-06-22 | JOHN OYLER | Chief Executive Officer | Sell | 3,714.00 | 182.78 | 678,838.98 | 32,546.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000086/0001651308-20-000086-index.htm |
| 2019-11-04 | Jane Huang | CMO, Hematology | Buy | 32,900.00 | 29.49 | 970,221.00 | 32,900.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000105/0001651308-19-000105-index.htm |
| 2020-06-17 | Jane Huang | CMO, Hematology | Buy | 48,438.00 | 331,902.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000076/0001651308-20-000076-index.htm | ||
| 2020-05-01 | JOHN OYLER | Chief Executive Officer | Sell | 302.00 | 143.17 | 43,237.13 | 3,333.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000046/0001651308-20-000046-index.htm |
| 2020-08-31 | JOHN OYLER | Chief Executive Officer | Sell | 5,707.00 | 241.14 | 1,376,172.28 | 3,354.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000146/0001651308-20-000146-index.htm |
| 2020-07-20 | Xiaodong Wang | Director | Sell | 2,652.00 | 251.31 | 666,470.14 | 3,418.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000103/0001651308-20-000103-index.htm |
| 2020-06-29 | JOHN OYLER | Chief Executive Officer | Sell | 1,100.00 | 192.84 | 212,127.63 | 35.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000089/0001651308-20-000089-index.htm |
| 2020-08-14 | JOHN OYLER | Chief Executive Officer | Sell | 2,817.00 | 210.84 | 593,949.24 | 3,590.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000122/0001651308-20-000122-index.htm |
| 2020-06-22 | JOHN OYLER | Chief Executive Officer | Sell | 1,772.00 | 181.79 | 322,138.26 | 36,260.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000086/0001651308-20-000086-index.htm |
| 2020-05-01 | JOHN OYLER | Chief Executive Officer | Sell | 1,000.00 | 142.46 | 142,461.60 | 3,635.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000046/0001651308-20-000046-index.htm |
| 2020-09-14 | JOHN OYLER | Chief Executive Officer | Sell | 6,877.00 | 250.56 | 1,723,094.93 | 3,646.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000153/0001651308-20-000153-index.htm |
| 2020-07-20 | Xiaodong Wang | Director | Sell | 1,000.00 | 250.33 | 250,332.00 | 3,700.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000103/0001651308-20-000103-index.htm |
| 2020-08-21 | JOHN OYLER | Chief Executive Officer | Sell | 3,103.00 | 237.80 | 737,882.23 | 37,685.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000125/0001651308-20-000125-index.htm |
| 2019-11-14 | Xiaodong Wang | Director | Sell | 704.00 | 194.12 | 136,662.17 | 3,796.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000117/0001651308-19-000117-index.htm |
| 2020-07-22 | JOHN OYLER | Chief Executive Officer | Sell | 1,505.00 | 241.40 | 363,307.00 | 3,800.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000105/0001651308-20-000105-index.htm |
| 2019-11-05 | Timothy Yung-Cheng Chen | Director | Sell | 200.00 | 187.38 | 37,475.56 | 3,800.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000104/0001651308-19-000104-index.htm |
| 2020-06-22 | JOHN OYLER | Chief Executive Officer | Sell | 800.00 | 180.50 | 144,400.96 | 38,032.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000086/0001651308-20-000086-index.htm |
| 2020-09-16 | JOHN OYLER | Chief Executive Officer | Sell | 13,140.00 | 255.14 | 3,352,505.44 | 3,823.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000153/0001651308-20-000153-index.htm |
| 2020-06-22 | JOHN OYLER | Chief Executive Officer | Sell | 900.00 | 179.58 | 161,626.23 | 38,832.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000086/0001651308-20-000086-index.htm |
| 2020-07-07 | Jane Huang | CMO, Hematology | Buy | 3,921.00 | 160.40 | 628,928.40 | 3,921.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000094/0001651308-20-000094-index.htm |
| 2019-11-14 | Xiaodong Wang | Director | Sell | 2,605.00 | 193.57 | 504,241.77 | 395.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000117/0001651308-19-000117-index.htm |
| 2019-12-17 | JOHN OYLER | Chief Executive Officer | Sell | 15,466.00 | 159.59 | 2,468,195.74 | 39,738.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000136/0001651308-19-000136-index.htm |
| 2020-07-29 | Jane Huang | CMO, Hematology | Sell | 400.00 | 212.53 | 85,011.00 | 399.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000106/0001651308-20-000106-index.htm |
| 2019-11-18 | Howard Liang | CFO & Chief Strategy Officer | Sell | 200.00 | 197.55 | 39,510.00 | 400.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000119/0001651308-19-000119-index.htm |
| 2019-12-16 | Jane Huang | CMO, Hematology | Sell | 100.00 | 168.90 | 16,890.00 | 400.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000135/0001651308-19-000135-index.htm |
| 2020-08-04 | JOHN OYLER | Chief Executive Officer | Sell | 301.00 | 224.05 | 67,438.96 | 400.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000108/0001651308-20-000108-index.htm |
| 2020-09-29 | JOHN OYLER | Chief Executive Officer | Sell | 1,609.00 | 283.11 | 455,527.37 | 400.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000180/0001651308-20-000180-index.htm |
| 2020-07-15 | Xiaobin Wu | President & GM China | Sell | 300.00 | 242.63 | 72,789.00 | 400.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000098/0001651308-20-000098-index.htm |
| 2020-07-17 | Xiaobin Wu | President & GM China | Sell | 300.00 | 240.00 | 72,000.00 | 400.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000102/0001651308-20-000102-index.htm |
| 2019-11-04 | Timothy Yung-Cheng Chen | Director | Buy | 4,000.00 | 41.01 | 164,040.00 | 4,000.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000104/0001651308-19-000104-index.htm |
| 2019-11-05 | Timothy Yung-Cheng Chen | Director | Buy | 4,000.00 | 41.01 | 164,040.00 | 4,000.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000104/0001651308-19-000104-index.htm |
| 2020-08-10 | Xiaodong Wang | Director | Sell | 400.00 | 214.83 | 85,933.00 | 406.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000120/0001651308-20-000120-index.htm |
| 2019-11-05 | Timothy Yung-Cheng Chen | Director | Sell | 1,892.00 | 189.56 | 358,639.76 | 408.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000104/0001651308-19-000104-index.htm |
| 2020-06-23 | Xiaodong Wang | Director | Sell | 1,845.00 | 185.58 | 342,388.46 | 4,155.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000085/0001651308-20-000085-index.htm |
| 2020-07-01 | Xiaodong Wang | Director | Sell | 690.00 | 189.19 | 130,543.93 | 4,157.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000092/0001651308-20-000092-index.htm |
| 2020-08-31 | JOHN OYLER | Chief Executive Officer | Sell | 3,312.00 | 242.15 | 802,017.03 | 42.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000146/0001651308-20-000146-index.htm |
| 2020-05-29 | Jane Huang | CMO, Hematology | Sell | 569.00 | 163.97 | 93,299.61 | 431.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000061/0001651308-20-000061-index.htm |
| 2020-08-05 | JOHN OYLER | Chief Executive Officer | Sell | 608.00 | 225.36 | 137,016.93 | 4,388.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000110/0001651308-20-000110-index.htm |
| 2020-09-01 | JOHN OYLER | Chief Executive Officer | Sell | 1,228.00 | 234.98 | 288,555.07 | 4,451.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000146/0001651308-20-000146-index.htm |
| 2019-11-14 | Xiaodong Wang | Director | Sell | 2,200.00 | 193.04 | 424,691.52 | 4,500.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000117/0001651308-19-000117-index.htm |
| 2020-07-22 | JOHN OYLER | Chief Executive Officer | Sell | 146.00 | 245.78 | 35,884.20 | 454.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000105/0001651308-20-000105-index.htm |
| 2019-12-17 | JOHN OYLER | Chief Executive Officer | Sell | 18,215.00 | 161.49 | 2,941,527.60 | 4,558.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000136/0001651308-19-000136-index.htm |
| 2020-07-01 | Xiaodong Wang | Director | Sell | 1,600.00 | 191.37 | 306,184.00 | 457.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000092/0001651308-20-000092-index.htm |
| 2020-08-20 | JOHN OYLER | Chief Executive Officer | Sell | 2,101.00 | 236.50 | 496,878.52 | 4,679.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000125/0001651308-20-000125-index.htm |
| 2020-07-20 | Xiaodong Wang | Director | Sell | 300.00 | 249.60 | 74,880.99 | 4,700.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000103/0001651308-20-000103-index.htm |
| 2020-05-01 | JOHN OYLER | Chief Executive Officer | Sell | 2,859.00 | 140.96 | 403,004.64 | 474.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000046/0001651308-20-000046-index.htm |
| 2020-06-08 | Xiaobin Wu | President & GM China | Sell | 1,125.00 | 171.20 | 192,604.84 | 475.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000066/0001651308-20-000066-index.htm |
| 2020-07-21 | JOHN OYLER | Chief Executive Officer | Sell | 4,500.00 | 253.60 | 1,141,183.80 | 4,894.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000104/0001651308-20-000104-index.htm |
| 2020-08-05 | JOHN OYLER | Chief Executive Officer | Sell | 1,894.00 | 224.28 | 424,786.89 | 4,996.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000110/0001651308-20-000110-index.htm |
| 2019-11-13 | Xiaodong Wang | Director | Buy | 50.00 | 50.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000117/0001651308-19-000117-index.htm | ||
| 2019-12-16 | Jane Huang | CMO, Hematology | Sell | 100.00 | 165.55 | 16,555.00 | 500.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000135/0001651308-19-000135-index.htm |
| 2020-09-17 | Xiaobin Wu | President & GM China | Sell | 3,500.00 | 260.20 | 910,711.90 | 500.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000161/0001651308-20-000161-index.htm |
| 2020-10-05 | Howard Liang | CFO & Chief Strategy Officer | Sell | 1,499.00 | 300.88 | 451,024.37 | 5,000.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000194/0001651308-20-000194-index.htm |
| 2020-09-02 | JOHN OYLER | Chief Executive Officer | Sell | 1,455.00 | 232.70 | 338,578.35 | 5,034.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000146/0001651308-20-000146-index.htm |
| 2020-07-22 | JOHN OYLER | Chief Executive Officer | Sell | 1,795.00 | 240.27 | 431,283.75 | 5,305.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000105/0001651308-20-000105-index.htm |
| 2020-09-14 | Howard Liang | CFO & Chief Strategy Officer | Sell | 6,478.00 | 249.97 | 1,619,316.67 | 5,441.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000152/0001651308-20-000152-index.htm |
| 2020-05-01 | Xiaobin Wu | President & GM China | Sell | 1,224.00 | 142.54 | 174,469.20 | 545.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000045/0001651308-20-000045-index.htm |
| 2019-12-17 | JOHN OYLER | Chief Executive Officer | Sell | 7,055.00 | 158.63 | 1,119,105.02 | 55,204.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000136/0001651308-19-000136-index.htm |
| 2020-06-24 | JOHN OYLER | Chief Executive Officer | Sell | 4,115.00 | 187.10 | 769,914.03 | 5,525.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000086/0001651308-20-000086-index.htm |
| 2020-09-01 | JOHN OYLER | Chief Executive Officer | Sell | 4,290.00 | 234.28 | 1,005,044.90 | 5,679.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000146/0001651308-20-000146-index.htm |
| 2020-09-29 | Jane Huang | CMO, Hematology | Sell | 730.00 | 280.65 | 204,874.79 | 570.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000182/0001651308-20-000182-index.htm |
| 2020-08-03 | JOHN OYLER | Chief Executive Officer | Sell | 3,567.00 | 222.14 | 792,383.01 | 5,807.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000108/0001651308-20-000108-index.htm |
| 2020-08-04 | JOHN OYLER | Chief Executive Officer | Sell | 2,209.00 | 220.62 | 487,360.40 | 5,922.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000108/0001651308-20-000108-index.htm |
| 2019-11-18 | Howard Liang | CFO & Chief Strategy Officer | Sell | 200.00 | 196.63 | 39,326.00 | 600.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000119/0001651308-19-000119-index.htm |
| 2019-12-16 | Jane Huang | CMO, Hematology | Sell | 800.00 | 161.93 | 129,541.36 | 600.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000135/0001651308-19-000135-index.htm |
| 2020-07-22 | JOHN OYLER | Chief Executive Officer | Sell | 300.00 | 244.63 | 73,389.00 | 600.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000105/0001651308-20-000105-index.htm |
| 2020-08-10 | Timothy Yung-Cheng Chen | Director | Sell | 500.00 | 214.66 | 107,332.00 | 600.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000121/0001651308-20-000121-index.htm |
| 2020-09-15 | JOHN OYLER | Chief Executive Officer | Sell | 12,799.00 | 254.95 | 3,263,157.53 | 6,008.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000153/0001651308-20-000153-index.htm |
| 2020-07-20 | Xiaodong Wang | Director | Sell | 5,430.00 | 250.39 | 1,359,601.95 | 6,070.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000103/0001651308-20-000103-index.htm |
| 2020-08-19 | JOHN OYLER | Chief Executive Officer | Sell | 6,221.00 | 235.23 | 1,463,351.52 | 6,100.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000125/0001651308-20-000125-index.htm |
| 2020-09-25 | Xiaodong Wang | Director | Sell | 4,380.00 | 280.29 | 1,227,682.90 | 620.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000176/0001651308-20-000176-index.htm |
| 2020-08-05 | JOHN OYLER | Chief Executive Officer | Sell | 3,767.00 | 226.21 | 852,136.08 | 621.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000110/0001651308-20-000110-index.htm |
| 2020-09-29 | JOHN OYLER | Chief Executive Officer | Sell | 10,827.00 | 281.16 | 3,044,160.46 | 6,245.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000180/0001651308-20-000180-index.htm |
| 2020-08-14 | JOHN OYLER | Chief Executive Officer | Sell | 2,298.00 | 209.55 | 481,556.47 | 6,407.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000122/0001651308-20-000122-index.htm |
| 2019-11-18 | Howard Liang | CFO & Chief Strategy Officer | Sell | 8,156.00 | 194.62 | 1,587,310.93 | 6,433.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000119/0001651308-19-000119-index.htm |
| 2020-09-02 | JOHN OYLER | Chief Executive Officer | Sell | 1,905.00 | 231.52 | 441,045.60 | 6,489.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000146/0001651308-20-000146-index.htm |
| 2020-10-05 | Howard Liang | CFO & Chief Strategy Officer | Sell | 2,001.00 | 300.08 | 600,469.08 | 6,499.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000194/0001651308-20-000194-index.htm |
| 2020-07-08 | JOHN OYLER | Chief Executive Officer | Sell | 4,841.00 | 201.58 | 975,868.63 | 6,688.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000093/0001651308-20-000093-index.htm |
| 2019-11-14 | Xiaodong Wang | Director | Sell | 2,500.00 | 192.19 | 480,482.25 | 6,700.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000117/0001651308-19-000117-index.htm |
| 2020-08-20 | JOHN OYLER | Chief Executive Officer | Sell | 3,845.00 | 235.22 | 904,410.52 | 6,780.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000125/0001651308-20-000125-index.htm |
| 2020-01-21 | Jane Huang | CMO, Hematology | Sell | 813.00 | 170.09 | 138,286.91 | 687.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000009/0001651308-20-000009-index.htm |
| 2020-08-05 | JOHN OYLER | Chief Executive Officer | Sell | 2,365.00 | 223.32 | 528,159.60 | 6,890.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000110/0001651308-20-000110-index.htm |
| 2020-08-21 | JOHN OYLER | Chief Executive Officer | Sell | 6,700.00 | 242.96 | 1,627,836.69 | 694.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000125/0001651308-20-000125-index.htm |
| 2020-06-26 | Jane Huang | CMO, Hematology | Sell | 700.00 | 200.29 | 140,203.98 | 700.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000087/0001651308-20-000087-index.htm |
| 2020-09-28 | JOHN OYLER | Chief Executive Officer | Sell | 1,800.00 | 281.04 | 505,873.98 | 700.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000180/0001651308-20-000180-index.htm |
| 2020-07-15 | Xiaobin Wu | President & GM China | Sell | 2,000.00 | 240.10 | 480,207.60 | 700.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000098/0001651308-20-000098-index.htm |
| 2020-06-23 | Xiaodong Wang | Director | Sell | 3,455.00 | 186.62 | 644,755.52 | 700.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000085/0001651308-20-000085-index.htm |
| 2020-08-04 | JOHN OYLER | Chief Executive Officer | Sell | 1,921.00 | 222.62 | 427,652.06 | 701.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000108/0001651308-20-000108-index.htm |
| 2020-07-22 | JOHN OYLER | Chief Executive Officer | Sell | 2,400.00 | 239.45 | 574,674.00 | 7,100.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000105/0001651308-20-000105-index.htm |
| 2020-07-20 | JOHN OYLER | Chief Executive Officer | Sell | 7,345.00 | 252.56 | 1,855,061.28 | 7,148.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000104/0001651308-20-000104-index.htm |
| 2020-09-03 | Jane Huang | CMO, Hematology | Sell | 1,411.00 | 232.94 | 328,671.85 | 717.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000147/0001651308-20-000147-index.htm |
| 2020-09-16 | JOHN OYLER | Chief Executive Officer | Sell | 300.00 | 256.86 | 77,057.01 | 723.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000153/0001651308-20-000153-index.htm |
| 2020-08-21 | JOHN OYLER | Chief Executive Officer | Sell | 2,471.00 | 241.62 | 597,032.64 | 7,394.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000125/0001651308-20-000125-index.htm |
| 2020-08-13 | JOHN OYLER | Chief Executive Officer | Sell | 3,743.00 | 214.44 | 802,653.79 | 7,488.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000122/0001651308-20-000122-index.htm |
| 2020-06-29 | Jane Huang | CMO, Hematology | Sell | 402.00 | 188.95 | 75,958.78 | 798.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000087/0001651308-20-000087-index.htm |
| 2020-07-29 | Jane Huang | CMO, Hematology | Sell | 200.00 | 211.31 | 42,262.00 | 799.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000106/0001651308-20-000106-index.htm |
| 2019-11-18 | Howard Liang | CFO & Chief Strategy Officer | Sell | 5,633.00 | 195.57 | 1,101,671.16 | 800.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000119/0001651308-19-000119-index.htm |
| 2019-11-18 | Jane Huang | CMO, Hematology | Sell | 500.00 | 193.63 | 96,813.00 | 800.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000118/0001651308-19-000118-index.htm |
| 2020-08-10 | Xiaodong Wang | Director | Sell | 400.00 | 213.15 | 85,260.00 | 806.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000120/0001651308-20-000120-index.htm |
| 2020-08-04 | JOHN OYLER | Chief Executive Officer | Sell | 2,575.00 | 219.56 | 565,372.67 | 8,131.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000108/0001651308-20-000108-index.htm |
| 2020-07-07 | JOHN OYLER | Chief Executive Officer | Sell | 5,474.00 | 199.01 | 1,089,391.14 | 8,318.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000093/0001651308-20-000093-index.htm |
| 2020-09-02 | JOHN OYLER | Chief Executive Officer | Sell | 3,300.00 | 230.50 | 760,641.42 | 8,394.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000146/0001651308-20-000146-index.htm |
| 2020-09-17 | Xiaodong Wang | Director | Sell | 4,916.00 | 260.26 | 1,279,421.45 | 84.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000162/0001651308-20-000162-index.htm |
| 2020-10-05 | Howard Liang | CFO & Chief Strategy Officer | Sell | 1,000.00 | 298.97 | 298,966.00 | 8,500.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000194/0001651308-20-000194-index.htm |
| 2020-08-12 | JOHN OYLER | Chief Executive Officer | Sell | 2,322.00 | 212.38 | 493,141.48 | 8,682.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000122/0001651308-20-000122-index.htm |
| 2020-01-21 | Jane Huang | CMO, Hematology | Sell | 600.00 | 171.27 | 102,762.00 | 87.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000009/0001651308-20-000009-index.htm |
| 2020-07-06 | JOHN OYLER | Chief Executive Officer | Sell | 7,701.00 | 196.62 | 1,514,203.73 | 8,861.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000093/0001651308-20-000093-index.htm |
| 2020-07-22 | JOHN OYLER | Chief Executive Officer | Sell | 1,000.00 | 243.36 | 243,355.00 | 900.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000105/0001651308-20-000105-index.htm |
| 2020-09-01 | JOHN OYLER | Chief Executive Officer | Sell | 1,000.00 | 238.46 | 238,461.00 | 900.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000146/0001651308-20-000146-index.htm |
| 2020-08-11 | Timothy Yung-Cheng Chen | Director | Sell | 1,000.00 | 212.41 | 212,407.00 | 903.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000121/0001651308-20-000121-index.htm |
| 2020-08-31 | JOHN OYLER | Chief Executive Officer | Sell | 2,200.00 | 240.15 | 528,326.26 | 9,061.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000146/0001651308-20-000146-index.htm |
| 2019-11-14 | Xiaodong Wang | Director | Sell | 800.00 | 191.03 | 152,826.00 | 9,200.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130819000117/0001651308-19-000117-index.htm |
| 2020-08-05 | JOHN OYLER | Chief Executive Officer | Sell | 2,399.00 | 222.16 | 532,961.36 | 9,255.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000110/0001651308-20-000110-index.htm |
| 2020-08-03 | JOHN OYLER | Chief Executive Officer | Sell | 12,020.00 | 221.43 | 2,661,546.53 | 9,374.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000108/0001651308-20-000108-index.htm |
| 2020-07-21 | JOHN OYLER | Chief Executive Officer | Sell | 3,896.00 | 252.34 | 983,118.98 | 9,394.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000104/0001651308-20-000104-index.htm |
| 2020-10-05 | Howard Liang | CFO & Chief Strategy Officer | Sell | 1,200.00 | 297.98 | 357,573.00 | 9,500.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000194/0001651308-20-000194-index.htm |
| 2020-07-22 | JOHN OYLER | Chief Executive Officer | Sell | 3,300.00 | 238.54 | 787,181.67 | 9,500.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000105/0001651308-20-000105-index.htm |
| 2020-06-24 | JOHN OYLER | Chief Executive Officer | Sell | 4,741.00 | 186.11 | 882,334.24 | 9,640.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000086/0001651308-20-000086-index.htm |
| 2020-06-22 | Xiaodong Wang | Director | Sell | 2,220.00 | 181.52 | 402,981.73 | 980.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000085/0001651308-20-000085-index.htm |
| 2020-08-21 | JOHN OYLER | Chief Executive Officer | Sell | 6,255.00 | 240.64 | 1,505,215.08 | 9,865.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000125/0001651308-20-000125-index.htm |
| 2020-09-01 | JOHN OYLER | Chief Executive Officer | Sell | 3,401.00 | 232.86 | 791,969.10 | 9,969.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000146/0001651308-20-000146-index.htm |
| 2020-07-29 | Jane Huang | CMO, Hematology | Sell | 700.00 | 208.91 | 146,237.00 | 999.00 | https://www.sec.gov/Archives/edgar/data/1651308/000165130820000106/0001651308-20-000106-index.htm |